JP4234137B2 - ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整 - Google Patents
ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整 Download PDFInfo
- Publication number
- JP4234137B2 JP4234137B2 JP2005518889A JP2005518889A JP4234137B2 JP 4234137 B2 JP4234137 B2 JP 4234137B2 JP 2005518889 A JP2005518889 A JP 2005518889A JP 2005518889 A JP2005518889 A JP 2005518889A JP 4234137 B2 JP4234137 B2 JP 4234137B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- composition
- useful
- silicone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 212
- 229960001915 hexamidine Drugs 0.000 title claims description 25
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title description 3
- -1 hexamidine compound Chemical class 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 24
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims 3
- 210000003491 skin Anatomy 0.000 description 100
- 229920001296 polysiloxane Polymers 0.000 description 56
- 239000012071 phase Substances 0.000 description 53
- 239000000839 emulsion Substances 0.000 description 47
- 239000000126 substance Substances 0.000 description 39
- 125000000217 alkyl group Chemical group 0.000 description 38
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 38
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 38
- 239000003995 emulsifying agent Substances 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 36
- 239000004205 dimethyl polysiloxane Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 229940008099 dimethicone Drugs 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 26
- 239000003921 oil Substances 0.000 description 25
- 230000003405 preventing effect Effects 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 22
- 239000013543 active substance Substances 0.000 description 21
- 235000000346 sugar Nutrition 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 150000002148 esters Chemical class 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 206010040844 Skin exfoliation Diseases 0.000 description 18
- 239000002537 cosmetic Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 239000000516 sunscreening agent Substances 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 15
- 238000004299 exfoliation Methods 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000002562 thickening agent Substances 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 235000021317 phosphate Nutrition 0.000 description 13
- 230000019612 pigmentation Effects 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000000475 sunscreen effect Effects 0.000 description 13
- 230000000699 topical effect Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 11
- 229940121363 anti-inflammatory agent Drugs 0.000 description 11
- 239000002260 anti-inflammatory agent Substances 0.000 description 11
- 239000002738 chelating agent Substances 0.000 description 11
- 239000003974 emollient agent Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 235000019156 vitamin B Nutrition 0.000 description 11
- 239000011720 vitamin B Substances 0.000 description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 229930003270 Vitamin B Natural products 0.000 description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 150000004492 retinoid derivatives Chemical class 0.000 description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- 230000037303 wrinkles Effects 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 210000000282 nail Anatomy 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 239000003760 tallow Substances 0.000 description 9
- LYRFLYHAGKPMFH-UHFFFAOYSA-N Amide-Octadecanoic acid Natural products CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 8
- 208000035484 Cellulite Diseases 0.000 description 8
- 206010049752 Peau d'orange Diseases 0.000 description 8
- 239000004721 Polyphenylene oxide Substances 0.000 description 8
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- 150000002170 ethers Chemical class 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 229920000570 polyether Polymers 0.000 description 8
- 229920002545 silicone oil Polymers 0.000 description 8
- 229930003799 tocopherol Natural products 0.000 description 8
- 239000011732 tocopherol Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 7
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 7
- 235000013162 Cocos nucifera Nutrition 0.000 description 7
- 244000060011 Cocos nucifera Species 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 7
- 229960003237 betaine Drugs 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 7
- 125000002091 cationic group Chemical group 0.000 description 7
- 239000003093 cationic surfactant Substances 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- 235000015424 sodium Nutrition 0.000 description 7
- 235000010384 tocopherol Nutrition 0.000 description 7
- 229960001295 tocopherol Drugs 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 6
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 6
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- 206010015967 Eye swelling Diseases 0.000 description 6
- 108010076876 Keratins Proteins 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- 235000005513 chalcones Nutrition 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 6
- 229940086555 cyclomethicone Drugs 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 229940068065 phytosterols Drugs 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 229940037312 stearamide Drugs 0.000 description 6
- 230000007306 turnover Effects 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- XJMNWALRJHPRBS-UHFFFAOYSA-N 2,3-dihydroxypropyl-[3-(docosanoylamino)propyl]-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CO XJMNWALRJHPRBS-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 206010040799 Skin atrophy Diseases 0.000 description 5
- 241000212749 Zesius chrysomallus Species 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000036232 cellulite Effects 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960003276 erythromycin Drugs 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 241000221931 Hypomyces rosellus Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 230000003255 anti-acne Effects 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 150000001789 chalcones Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 235000001671 coumarin Nutrition 0.000 description 4
- 150000004775 coumarins Chemical class 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 229930003949 flavanone Natural products 0.000 description 4
- 150000002208 flavanones Chemical class 0.000 description 4
- 235000011981 flavanones Nutrition 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 229920002379 silicone rubber Polymers 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 229940032091 stigmasterol Drugs 0.000 description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 4
- 235000016831 stigmasterol Nutrition 0.000 description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N 3-(4-Hydroxyphenyl)chroman-7-ol Chemical compound C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 229940085262 cetyl dimethicone Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- OSSCGHSWPYDTQZ-UHFFFAOYSA-N diazanium hexadecanoate chloride Chemical compound [Cl-].[NH4+].C(CCCCCCCCCCCCC)CC(=O)[O-].[NH4+] OSSCGHSWPYDTQZ-UHFFFAOYSA-N 0.000 description 3
- 229940120503 dihydroxyacetone Drugs 0.000 description 3
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 3
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 3
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 230000036252 glycation Effects 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229940074358 magnesium ascorbate Drugs 0.000 description 3
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000002884 skin cream Substances 0.000 description 3
- 230000036620 skin dryness Effects 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 2
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical group OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 150000001253 acrylic acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 229960005193 avobenzone Drugs 0.000 description 2
- GDCXBZMWKSBSJG-UHFFFAOYSA-N azane;4-methylbenzenesulfonic acid Chemical compound [NH4+].CC1=CC=C(S([O-])(=O)=O)C=C1 GDCXBZMWKSBSJG-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- WLCFKPHMRNPAFZ-UHFFFAOYSA-M didodecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC WLCFKPHMRNPAFZ-UHFFFAOYSA-M 0.000 description 2
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 2
- NTLIJZACUWTZFB-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;2-hydroxypropanoate Chemical compound CC(O)C(O)=O.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C NTLIJZACUWTZFB-UHFFFAOYSA-N 0.000 description 2
- RSHHCURRBLAGFA-UHFFFAOYSA-M dimethyl-di(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC RSHHCURRBLAGFA-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- PGQAXGHQYGXVDC-UHFFFAOYSA-N dodecyl(dimethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN(C)C PGQAXGHQYGXVDC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 2
- 229960001715 hexamidine isethionate Drugs 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 2
- YAGMLECKUBJRNO-UHFFFAOYSA-N octyl 4-(dimethylamino)benzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N(C)C)C=C1 YAGMLECKUBJRNO-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N ortho-phenyl-phenol Natural products OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940106026 phenoxyisopropanol Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940100459 steareth-20 Drugs 0.000 description 2
- 229940100458 steareth-21 Drugs 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229960001296 zinc oxide Drugs 0.000 description 2
- 239000002888 zwitterionic surfactant Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- GSTSUZHIVMCRLR-RVZXSAGBSA-N (2s)-2,6-diaminohexanoic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.NCCCC[C@H](N)C(O)=O GSTSUZHIVMCRLR-RVZXSAGBSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- AQSGIPQBQYCRLQ-UHFFFAOYSA-N (6,6-dihydroxy-4-methoxycyclohexa-2,4-dien-1-yl)-phenylmethanone Chemical compound C1=CC(OC)=CC(O)(O)C1C(=O)C1=CC=CC=C1 AQSGIPQBQYCRLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- VFOKYTYWXOYPOX-PTNGSMBKSA-N (e)-2,3-diphenylprop-2-enenitrile Chemical compound C=1C=CC=CC=1C(/C#N)=C\C1=CC=CC=C1 VFOKYTYWXOYPOX-PTNGSMBKSA-N 0.000 description 1
- 0 *c(c(*)c1*)c(*)c(*)c1I Chemical compound *c(c(*)c1*)c(*)c(*)c1I 0.000 description 1
- MMEXPSCGRYPZKY-UHFFFAOYSA-N 1-(3-bromoindazol-2-yl)ethanone Chemical compound C1=CC=CC2=C(Br)N(C(=O)C)N=C21 MMEXPSCGRYPZKY-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- GUPMCMZMDAGSPF-UHFFFAOYSA-N 1-phenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1[C](C=C[CH2])C1=CC=CC=C1 GUPMCMZMDAGSPF-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- XPKVYKWWLONHDF-UHFFFAOYSA-N 2,3-dihydroxy-3-(2-hydroxyphenyl)prop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1O XPKVYKWWLONHDF-UHFFFAOYSA-N 0.000 description 1
- DRBARRGCABOUIE-UHFFFAOYSA-N 2,3-dihydroxy-3-phenylprop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1 DRBARRGCABOUIE-UHFFFAOYSA-N 0.000 description 1
- WZPLEIAOQJXZJX-UHFFFAOYSA-N 2,3-dihydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C(O)=CC2=C1 WZPLEIAOQJXZJX-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- JWNWCEAWZGLYTE-UHFFFAOYSA-N 2-(trimethylazaniumyl)butanoate Chemical compound CCC(C([O-])=O)[N+](C)(C)C JWNWCEAWZGLYTE-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- AMRBZKOCOOPYNY-QXMHVHEDSA-N 2-[dimethyl-[(z)-octadec-9-enyl]azaniumyl]acetate Chemical compound CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O AMRBZKOCOOPYNY-QXMHVHEDSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- OBWBSSIUKXEALB-UHFFFAOYSA-N 2-aminoethanol;2-hydroxypropanamide Chemical compound NCCO.CC(O)C(N)=O OBWBSSIUKXEALB-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JCTNVNANPZAULC-UHFFFAOYSA-N 2-methylbenzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=C(O3)C)=C3C=CC2=C1 JCTNVNANPZAULC-UHFFFAOYSA-N 0.000 description 1
- FIISKTXZUZBTRC-UHFFFAOYSA-N 2-phenyl-1,3-benzoxazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2O1 FIISKTXZUZBTRC-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- ZCJRGONXXDDVLB-UHFFFAOYSA-N 28-Isofucosterolacetat Natural products CC=C(CCC(C)C1CCC2C3CCC4CC(CCC4(C)C3CCC12C)OC(=O)C)/C(C)C ZCJRGONXXDDVLB-UHFFFAOYSA-N 0.000 description 1
- HMKKFLSUPRUBOO-IUPFWZBJSA-N 3,4-dihydroxy-5-[3,4,5-tris[[(z)-octadec-9-enoyl]oxy]benzoyl]oxybenzoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(O)=O)O)=C1 HMKKFLSUPRUBOO-IUPFWZBJSA-N 0.000 description 1
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- BLNXQXNMBAGIHY-UHFFFAOYSA-N 3-hydroxy-6-phenylbenzene-1,2-disulfonic acid Chemical compound OS(=O)(=O)C1=C(S(O)(=O)=O)C(O)=CC=C1C1=CC=CC=C1 BLNXQXNMBAGIHY-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- ZCKGLNCGHWEPBZ-UHFFFAOYSA-N 3-phenylprop-2-enoyl 2-oxoheptanoate Chemical compound CCCCCC(=O)C(=O)OC(=O)C=CC1=CC=CC=C1 ZCKGLNCGHWEPBZ-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- KVOJTUXGYQVLAJ-UHFFFAOYSA-N 6,7-dihydroxy-4-methylcoumarin Chemical compound C1=C(O)C(O)=CC2=C1OC(=O)C=C2C KVOJTUXGYQVLAJ-UHFFFAOYSA-N 0.000 description 1
- HRRVLSKRYVIEPR-UHFFFAOYSA-N 6-hydroxy-5-nitroso-1H-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(N=O)C(O)=N1 HRRVLSKRYVIEPR-UHFFFAOYSA-N 0.000 description 1
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 1
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000159174 Commiphora Species 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical class OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- MQYXUWHLBZFQQO-CWFQSGEHSA-N Lupenol Natural products C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@H](C(=C)C)[C@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-CWFQSGEHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241001103643 Rubia Species 0.000 description 1
- 240000009235 Rubia cordifolia Species 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 240000002913 Trifolium pratense Species 0.000 description 1
- GTTSNKDQDACYLV-UHFFFAOYSA-N Trihydroxybutane Chemical compound CCCC(O)(O)O GTTSNKDQDACYLV-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 229940098323 ammonium cocoyl isethionate Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940047187 benzoresorcinol Drugs 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 229940033631 carrageenan sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002322 conducting polymer Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LUNQZVCDZKODKF-PFVVTREHSA-L copper acetic acid (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate (2S)-6-amino-2-[[(2S)-2-[(2-amino-1-oxidoethylidene)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate hydron Chemical compound [Cu+2].CC(O)=O.CC(O)=O.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 LUNQZVCDZKODKF-PFVVTREHSA-L 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 1
- HOIXTKAYCMNVMY-PVOAASPHSA-N daphnin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-PVOAASPHSA-N 0.000 description 1
- HOIXTKAYCMNVMY-UHFFFAOYSA-N daphnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-UHFFFAOYSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- PFCBRXGBIQWFED-UHFFFAOYSA-N didodecyl(methyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[NH+](C)CCCCCCCCCCCC PFCBRXGBIQWFED-UHFFFAOYSA-N 0.000 description 1
- SWWQNNDPJXYCNJ-UHFFFAOYSA-N didodecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCNCCCCCCCCCCCC SWWQNNDPJXYCNJ-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- RNMIVNUNMNQFRD-UHFFFAOYSA-N dihexadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC RNMIVNUNMNQFRD-UHFFFAOYSA-N 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 description 1
- PFKRTWCFCOUBHS-UHFFFAOYSA-N dimethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)C PFKRTWCFCOUBHS-UHFFFAOYSA-N 0.000 description 1
- XXAXQNQZAITMFD-UHFFFAOYSA-N dimethyl(propyl)azanium;octadecanamide;chloride Chemical compound [Cl-].CCC[NH+](C)C.CCCCCCCCCCCCCCCCCC(N)=O XXAXQNQZAITMFD-UHFFFAOYSA-N 0.000 description 1
- LVXUNJWLKCUTNF-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C LVXUNJWLKCUTNF-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- QHNXEVRKFKHMRL-UHFFFAOYSA-N dimethylazanium;acetate Chemical compound CNC.CC(O)=O QHNXEVRKFKHMRL-UHFFFAOYSA-N 0.000 description 1
- PGZPBNJYTNQMAX-UHFFFAOYSA-N dimethylazanium;methyl sulfate Chemical compound C[NH2+]C.COS([O-])(=O)=O PGZPBNJYTNQMAX-UHFFFAOYSA-N 0.000 description 1
- KGOGNDXXUVELIQ-UHFFFAOYSA-N dioctadecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC KGOGNDXXUVELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- QVKQJEWZVQFGIY-UHFFFAOYSA-N dipropyl hydrogen phosphate Chemical compound CCCOP(O)(=O)OCCC QVKQJEWZVQFGIY-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VZXFEELLBDNLAL-UHFFFAOYSA-N dodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH3+] VZXFEELLBDNLAL-UHFFFAOYSA-N 0.000 description 1
- TWFQJFPTTMIETC-UHFFFAOYSA-N dodecan-1-amine;hydron;chloride Chemical compound [Cl-].CCCCCCCCCCCC[NH3+] TWFQJFPTTMIETC-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- DLFDEDJIVYYWTB-UHFFFAOYSA-N dodecyl(dimethyl)azanium;bromide Chemical compound Br.CCCCCCCCCCCCN(C)C DLFDEDJIVYYWTB-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- VNSFGLSIVSOPEC-UHFFFAOYSA-N guanidine;urea Chemical compound NC(N)=N.NC(N)=O VNSFGLSIVSOPEC-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- XQSBLCWFZRTIEO-UHFFFAOYSA-N hexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH3+] XQSBLCWFZRTIEO-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- ZWGTVKDEOPDFGW-UHFFFAOYSA-N hexadecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH3+] ZWGTVKDEOPDFGW-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-WGMIZEQOSA-N isofucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC/C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-WGMIZEQOSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 125000005644 linolenyl group Chemical group 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- QUGJCUCHMFJZMD-UHFFFAOYSA-N methyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)CCCCCCCCCCCCCCCCCC QUGJCUCHMFJZMD-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VHDPPDRSCMVFAV-UHFFFAOYSA-N n,n-dimethylhexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH+](C)C VHDPPDRSCMVFAV-UHFFFAOYSA-N 0.000 description 1
- QMDUPVPMPVZZGK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)C QMDUPVPMPVZZGK-UHFFFAOYSA-N 0.000 description 1
- HSEULMYFIGIMSZ-UHFFFAOYSA-N n,n-dimethylpropan-1-amine;2-hydroxypropanoic acid;octadecanamide Chemical compound CCCN(C)C.CC(O)C(O)=O.CCCCCCCCCCCCCCCCCC(N)=O HSEULMYFIGIMSZ-UHFFFAOYSA-N 0.000 description 1
- UNAFTICPPXVTTN-UHFFFAOYSA-N n-dodecyldodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH2+]CCCCCCCCCCCC UNAFTICPPXVTTN-UHFFFAOYSA-N 0.000 description 1
- ALQWDAJTEFASRJ-UHFFFAOYSA-N n-hexadecylhexadecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC ALQWDAJTEFASRJ-UHFFFAOYSA-N 0.000 description 1
- IZXDTJXEUISVAJ-UHFFFAOYSA-N n-methyl-n-octadecyloctadecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)CCCCCCCCCCCCCCCCCC IZXDTJXEUISVAJ-UHFFFAOYSA-N 0.000 description 1
- FFJMLWSZNCJCSZ-UHFFFAOYSA-N n-methylmethanamine;hydrobromide Chemical compound Br.CNC FFJMLWSZNCJCSZ-UHFFFAOYSA-N 0.000 description 1
- KTAFYYQZWVSKCK-UHFFFAOYSA-N n-methylmethanamine;nitric acid Chemical compound CNC.O[N+]([O-])=O KTAFYYQZWVSKCK-UHFFFAOYSA-N 0.000 description 1
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229950002083 octabenzone Drugs 0.000 description 1
- YHIXOVNFGQWPFW-UHFFFAOYSA-N octadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH3+] YHIXOVNFGQWPFW-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical group CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- YLSUMFQEBHBMQB-OOFFSTKBSA-M potassium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydrox Chemical compound [K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O YLSUMFQEBHBMQB-OOFFSTKBSA-M 0.000 description 1
- HOZMBDKPRFLCKN-UHFFFAOYSA-M potassium;2-[[9-(carboxymethylamino)-9-oxononanoyl]amino]acetate Chemical compound [K+].OC(=O)CNC(=O)CCCCCCCC(=O)NCC([O-])=O HOZMBDKPRFLCKN-UHFFFAOYSA-M 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 1
- 229940045998 sodium isethionate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical group [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- HYHAWELIVMOSBT-UHFFFAOYSA-M sodium;2-aminopentadecanoate Chemical compound [Na+].CCCCCCCCCCCCCC(N)C([O-])=O HYHAWELIVMOSBT-UHFFFAOYSA-M 0.000 description 1
- LADXKQRVAFSPTR-UHFFFAOYSA-M sodium;2-hydroxyethanesulfonate Chemical compound [Na+].OCCS([O-])(=O)=O LADXKQRVAFSPTR-UHFFFAOYSA-M 0.000 description 1
- LEEHDJJMXGSXDH-UHFFFAOYSA-M sodium;2-octadecanoyloxyethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCCS([O-])(=O)=O LEEHDJJMXGSXDH-UHFFFAOYSA-M 0.000 description 1
- IWMMSZLFZZPTJY-UHFFFAOYSA-M sodium;3-(dodecylamino)propane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCNCCCS([O-])(=O)=O IWMMSZLFZZPTJY-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229940033331 soy sterol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- DIORMHZUUKOISG-UHFFFAOYSA-N sulfoformic acid Chemical compound OC(=O)S(O)(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cosmetics (AREA)
Description
a)ヘキサミジン、その塩及び誘導体から成る群から選択される安全且つ有効な量のヘキサミジン化合物と、
b)糖アミン、ビタミンB3、レチノイド、ペプチド、フィトステロール、ブチル化ヒドロキシトルエン及びブチル化ヒドロキシアニソール、これらの誘導体、及びこれらの組合せから成る群から選択される安全且つ有効な量の1以上のスキンケア活性物質と、
c)ヘキサミジン及びスキンケア活性物質のための皮膚科学的に許容可能なキャリアとを含む。
A.ヘキサミジン化合物
本発明の局所的に適用する組成物はまた、安全且つ有効な量の1つ以上のヘキサミジン及びその塩を含む。より好ましくは、ヘキサミジンはヘキサミジンイセチオネートである。
本発明は、糖アミン、ビタミンB3、レチニルプロピオネート、フィトステロール、ブチル化ヒドロキシトルエン及びブチル化ヒドロキシアニソール、これらの誘導体及びそれらの組合せから成る群から選択される1以上のスキンケア活性物質を包含する。
本発明の組成物は安全且つ有効な量の糖アミン(それはアミノ糖としても既知である)を包含する。本明細書で使用する時、「糖アミン」とは、6炭素の糖のアミン誘導体のことをいう。好ましくは組成物は、組成物の約0.001重量%〜約20重量%、より好ましくは約0.01重量%〜約15重量%、更により好ましくは約0.1重量%〜約10重量%、最も好ましくは約0.5重量%〜約5重量%の糖アミンを含有する。
本発明の組成物は、安全且つ有効な量のビタミンB3化合物を包含する。ビタミンB3化合物は、同時係属の米国特許出願第08/834,010号(1997年4月11日出願)(PCT国際公開特許WO97/39733A1(1997年10月30日に公開)に対応)に記載されるように、皮膚の状態を調整するのに特に有用である。好ましくは、組成物は、組成物の約0.01重量%〜約50重量%、より好ましくは、約0.1重量%〜約20重量%、更により好ましくは約0.5重量%〜約10重量%、より一層好ましくは、約1重量%〜約5重量%、最も好ましくは約2重量%〜約5重量%のビタミンB3化合物を含有する。
本発明の組成物は、安全且つ有効な量のレチノイドを、結果として得られる組成物が、ケラチン組織状態の調整、好ましくは目に見える及び/又は触知できる皮膚の不連続性の調整、より好ましくは皮膚老化の徴候の調整のために安全且つ有効であるように含有してもよい。好ましくは組成物は、組成物の約0.001重量%〜約10重量%、より好ましくは約0.005重量%〜約2重量%、更により好ましくは約0.01重量%〜約1重量%、更により好ましくは約0.01重量%〜約0.5重量%のレチノイドを含有する。組成物において用いられる最適な濃度は選択される特定のレチノイドに左右されるが、その理由は、それらの効力が著しく異なるからである。
本発明の組成物は、ジ−、トリ−、テトラ−、ペンタ−ペプチド、及び誘導体が挙げられるが、これらに限定されない安全且つ有効な量のペプチドを含有してもよい。組成物は好ましくは、組成物の約1×10-6重量%〜約20重量%、より好ましくは約1×10-6重量%〜約10重量%、更により好ましくは約1×10-5重量%〜約5重量%を含有する。
本発明の局所的に適用する組成物は、β−シトステロール、カンペステロール、ブラジカステロール、δ−5−アベナステロール、ルペノール、α−スピナステロール、スチグマステロール、これらの誘導体、類縁体、及びこれらの組合せから成る群から選択される、1つ以上の安全且つ有効な量のフィトステロールを含む。更に好ましくは、フィトステロールは、β−シトステロール、カンペステロール、ブラジカステロール、スチグマステロール、これらの誘導体、及びこれらの組合せから成る群から選択される。更により好ましくは、フィトステロールは、β−シトステロール、カンペステロール、ブラジカステロール、スチグマステロール、及びこれらの組合せから成る群から選択される。最も好ましくは、フィトステロールはスチグマステロールである。
本発明の局所的に適用する組成物は、安全且つ有効な量のBHT又はBHAを含む。本明細書で有用なBHTは、次の一般構造で記載することができる:
Yは、H、OH、OR5、COOR5、アルキル、シクロアルキル、ヘテロアルキル、ヘテロシクロアルキル、芳香族、ヘテロ芳香族、カルボキサミド、スルホンアミド、カルバメート、尿素及びトリアルキルシリルから成る群から選択され;
R1、R2、R3及びR4は、アルキル、シクロアルキル、ヘテロアルキル、ヘテロシクロアルキル、芳香族、ヘテロ芳香族、OR5、カルボキサミド、スルホンアミド、ホルミル、アシル、カルボキシル、カルボキシレート、カルバメート、尿素、トリアルキルシリル、ヒドロキシル及び水素から成る群から選択され;
R5は、アルキル、シクロアルキル、ヘテロアルキル、ヘテロシクロアルキル、芳香族、ヘテロ芳香族、トリアルキルシリル、アシル及び水素から成る群から選択される。
本発明の局所的に適用する組成物はまた、ヘキサミジン組成物のための皮膚科学的に許容可能なキャリアも含む。本明細書で使用する時、「皮膚科学的に許容可能なキャリア」という語句は、キャリアがケラチン組織への局所的な適用に好適であり、良好な審美特性を有し、本発明の活性物質及びその他のいずれの構成成分とも適合性があり、安全性又は毒性についていずれの問題も起こさないことを意味する。安全且つ有効な量のキャリアは、組成物の約50%〜約99.99%、好ましくは約60%〜約99.9%、より好ましくは約70〜約98%、最も好ましくは約80〜約95%である。
シリコーン中水型エマルションは、連続的なシリコーン相と分散した水性相を含有する。
本発明の好ましいシリコーン中水型エマルションは、約1〜約60重量%、好ましくは約5〜約40重量%、更に好ましくは約10〜約20重量%の連続的なシリコーン相を含む。連続的なシリコーン相は、以下に説明するような不連続な水性相を含有するか、又は取り囲む外部相として存在する。
本発明の局所用組成物は、約30%〜約90%、より好ましくは約50%〜約85%、最も好ましくは約70%〜約80%の分散した水性相を含む。エマルション技術では、「分散相」という用語は、当業者には周知であり、相が、連続相中に懸濁した又は連続相に囲まれた小粒子又は液滴として存在することを意味する。分散相は、内部相又は不連続相としても既知である。分散した水性相は、前述の連続的なシリコーン相に懸濁し取り囲まれた小さな水性粒子又は液滴の分散である。
本発明のシリコーン中水エマルションは、好ましくは乳化剤を含む。好ましい実施形態において、組成物は、組成物の約0.1重量%〜約10重量%の乳化剤、より好ましくは約0.5重量%〜約7.5重量%、最も好ましくは約1重量%〜約5重量%の乳化剤を含有する。乳化剤は、連続的なシリコーン相に水性相を分散し、懸濁するのを助ける。
及び
−(CH2)n−O−(CH2CHR3O)m−(CH2CHR4O)o−H
式中、nは3〜約10の整数であり;R3及びR4は、R3及びR4が、同時に同じものとならないようにH及びC1〜C6の直鎖又は分枝鎖アルキルから成る群より選択され;m、o、x、及びyは、分子の全分子量が約200〜約10,000,000になるように選択され、m、o、x、及びyは、m及びoが同時にゼロにならないように、独立してゼロ以上の整数から選択され、zは独立して1以上の整数から選択される。これらのコポリオールの位置異性体が生成し得ることが認識される。R3及びR4基を含有するR2部分について前述した化学的表現は、限定的ではなく、便宜上示したものである。
−(CH2)n−O−R5
であり、式中、R5は、カチオン、アニオン、両性イオン、又は双性イオン部分である。
その他の好ましい局所用キャリアには、連続的な水相及びそこに分散している疎水性の水不溶性相(「油相」)を有する水中油型エマルションが挙げられる。水中油型エマルションを含む好適なキャリアの例は、米国特許第5,073,371号(1991年12月17日ターナー・D.J.(Turner,D.J.)らに発行)、及び米国特許第5,073,372号(1991年12月17日ターナー・D.J.(Turner,D.J.)らに発行)に記載されている。構造剤、親水性の界面活性剤及び水を含有する、特に好ましい水中油型エマルションについては、以下に詳述する。
好ましい水中油型エマルションは、液晶ジェルの網目構造の構成を補佐するための構造剤を含む。理論によって束縛されるものではないが、構造剤は、組成物の安定性に寄与する組成物に流動学的特性を供給する助けをすると考えられている。構造剤はまた乳化剤又は界面活性剤として機能してもよい。好ましい本発明の組成物は、組成物の約0.5重量%〜約20重量%、更に好ましくは約1重量%〜約10重量%、最も好ましくは約1重量%〜約5重量%の構造剤を含む。
好ましい水中油型エマルションは、約0.05重量%〜約10重量%、好ましくは約1重量%〜約6重量%、より好ましくは約1重量%〜約3重量%の少なくとも1つの親水性界面活性剤を含み、この親水性界面活性剤は疎水性の物質を水相に分散することができる。界面活性剤は少なくとも、水に分散するのに十分なだけ親水性でなければならない。
式中、R1は約8〜約24個、好ましくは約10〜約16個の炭素原子を持つ直鎖または分枝鎖、飽和脂肪族炭化水素ラジカルから成る群から選択され、Mは、陽イオンである。更にその他の陰イオン性合成界面活性剤には、約12〜約24個の炭素原子を有するスクシナメート、オレフィンスルホネート、及びβ−アルキルオキシアルカンスルホネートとして示される部類が挙げられる。このような物質の例は、ラウリル硫酸ナトリウム及びラウリル硫酸アンモニウムである。
好ましい水中油型エマルションは、局所用キャリアの約25重量%〜約98重量%、好ましくは約65重量%〜約95重量%、更に好ましくは約70重量%〜約90重量%の水を含む。
ローションやクリームが挙げられるがこれらに限定されない、本発明の局所用組成物は、皮膚科学的に許容可能な皮膚軟化剤を含んでもよい。このような組成物は、好ましくは約2%〜約50%の皮膚軟化剤を含有する。本明細書で使用する時、「皮膚軟化剤」とは、乾燥の予防又は緩和並びに、皮膚の保護に有用な物質のことをいう。多種多様の好適な皮膚軟化剤が既知であり、本明細書で使用してもよい。サガリン(Sagarin)の「化粧品、科学と技術(Cosmetics,ScienceandTechnology)」、第2版、第1巻32〜43頁(1972年)は皮膚軟化剤として好適な物質の多数の例を含み、本明細書に参考として組み入れる。好ましい皮膚軟化剤は、グリセリンである。グリセリンは、好ましくは約0.001〜約20%、より好ましくは約0.01〜約10%、最も好ましくは約0.1〜約7%、例えば5%の量で用いられる。
本発明の組成物は、所与の製品の種類に従来用いられる他の様々な成分を、それらが本発明の利益を容認し難いほど変更しないという条件で含有してもよい。
安全且つ有効な量、より好ましくは組成物の約0.01重量%〜約10重量%、更により好ましくは約0.5重量%〜約5重量%、また好ましくは約0.1重量%〜約2重量%の剥離活性物質を本発明の組成物に添加してもよい。剥離活性物質は、本発明の皮膚外観効果を増進させる。例えば、剥離活性物質は皮膚の質感(例えば、滑らかさ)を改善する傾向がある。本明細書に用いるのに好適な1つの剥離系は、スルフヒドリル化合物及び双極性界面活性剤を含み、PCT国際公開特許96/01101(1996年1月18日出願)に相当する米国特許第5,681,852号(ドナルド・L・ビッセット(Donald L.Bissett)の名において1997年10月28日発行)に記載されている。本明細書での使用に好適な別の剥離系は、サリチル酸及び双極性界面活性剤を含み、PCT国際公開特許95/13048(1995年5月18日公開)に相当し、出願第08/209,041号(ビセット(Bissett)の名において1994年3月9日出願、現在放棄)の継続である、米国特許第5,652,228号(1997年7月29日発行)に記載されている。これらの特許出願に記載されているような双性イオン界面活性剤はまた、本明細書においても剥離剤として有用であり、セチルベタインが特に好ましい。
本発明の組成物は、安全且つ有効な量の1つ以上の抗ニキビ活性物質を含んでもよい。有用な抗ニキビ活性物質の例には、レゾルシノール、イオウ、サリチル酸、エリスロマイシン、亜鉛などが挙げられる。好適な抗ニキビ活性物質の更なる例は、米国特許第5,607,980号(マカティ(McAtee)ら、1997年3月4日発行)により詳細に記載されている。
本発明の組成物は、安全且つ有効な量の1つ以上の抗しわ活性物質又は抗萎縮活性物質を更に含んでもよい。本発明の組成物に用いるのに好適な代表的な抗しわ/抗皮膚萎縮活性物質には、イオウ含有D及びLアミノ酸及びこれらの誘導体と塩、特にN−アセチル誘導体が挙げられ、その好ましい例は、N−アセチル−L−システインであり;チオール、例えば、エタンチオール;ヒドロキシ酸(例えば、サリチル酸、グリコール酸)、ケト酸(例えば、ピルビン酸)、アスコルビン酸(ビタミンC)、フィチン酸、リポ酸;リソフォスファチド酸、皮膚剥脱剤(例えば、フェノールなど)、フラボノイド(例えば、フラバノン、カルコン、イソフラボン、フラボンなど)、スチルベン、シンナメート、レスベラトロル、カイネチン、ゼアチン、ジメチルアミノエタノール、自然源(例えば、大豆ペプチド)からのペプチド、糖酸の塩(例えば、グルコン酸マンガン)、テルペンアルコール(例えば、ファルネソール)、ペプチド、及び特にケラチン組織の状態、例えば、皮膚の状態を調整する場合に本発明のケラチン組織の外観の利益を強化するレチノイド、並びにその他のビタミンB化合物(例えば、チアミン(ビタミンB1)、パントテン酸(ビタミンB5)、カルニチン(ビタミンBt)、リボフラビン(ビタミンB2)、コバラミン(ビタミンB12)、パンガム酸又はジイソプロピルアミンジクロロアセテート(ビタミンB15群)、並びにこれらの誘導体及び塩(例えば、HCl塩又はカルシウム塩))が挙げられる。
本発明の組成物は、安全且つ有効な量の酸化防止剤/ラジカルスカベンジャーを含んでもよい。酸化防止剤/ラジカルスカベンジャーは、鱗屑の剥がれの増加又は角質層のきめの変化の原因となり得る紫外線に対して、またその他の皮膚損傷の原因となり得る環境要因に対して、特に有用に防御する。
本発明の組成物は更に、安全且つ有効な量のキレーター又はキレート化剤を含んでもよい。本明細書で使用するとき、「キレーター」又は「キレート剤」とは、金属イオンが容易に化学反応に加わったり、化学反応を触媒したりしないように、錯体を形成することによって系から金属イオンを除くことができる活性物質を意味する。キレート化剤を含むことは、過剰な鱗屑又は皮膚組織変化の一因となるような紫外線照射から、また皮膚の損傷を起こし得るようなその他の環境化学物質から、保護するためにとりわけ有用である。
本発明の組成物は、任意にフラボノイド化合物を含んでもよい。フラボノイドは、米国特許第5,686,082号及び第5,686,367号に広範に開示されており、これらを両方共本明細書に参考として組み込む。本発明で使用するのに適しているフラボノイドの例は、非置換フラバノン、モノ−置換フラバノン及びこれらの混合物から成る群から選択されるフラバノン;非置換カルコン、モノ−置換カルコン、ジ−置換カルコン、トリ−置換カルコン、及びこれらの混合物から成る群から選択されるカルコン;非置換フラボン、モノ−置換フラボン、ジ−置換フラボン、及びこれらの混合物から成る群から選択されるフラボン;1つ以上のイソフラボン;非置換クマリン、モノ−置換クマリン、ジ−置換クマリン、及びこれらの混合物から成る群から選択されるクマリン;非置換クロモン、モノ−置換クロモン、ジ−置換クロモン、及びこれらの混合物から成る群から選択されるクロモン;1つ以上のジクマロール;1つ以上のクロマノン;1つ以上のクロマノール;これらの異性体(例えば、シス/トランス異性体);並びにこれらの混合物である。本明細書で使用するとき、「置換した」という用語は、フラボノイドの1個又は複数個の水素原子が独立して、ヒドロキシル、C1〜C8アルキル、C1〜C4アルコキシル、O−グリコシド等、又はこれら置換基の混合で置換されるフラボノイドを意味する。
安全かつ有効な量の抗炎症剤を本発明の組成物に加えることができ、その量は、好ましくは組成物の約0.01%〜約10%、更に好ましくは約0.5%〜約5%である。抗炎症剤は、本発明における皮膚の外観に関する利点を高め、例えばそのような薬剤は、更に均一で好ましい皮膚の色調又は色に寄与する。そのような薬剤は効力が様々に異なるために、組成物中で使用される抗炎症剤の正確な量は、利用する特定の抗炎症剤によって決まる。
本発明の組成物はまた、安全且つ有効な量の抗セルライト剤を含んでもよい。好適な抗セルライト剤としては、キサンチン化合物(例えば、カフェイン、テオフィリン、テオブロミン、及びアミノフィリン)を挙げることができるが、これらに限定されない。
本発明の組成物はまた、安全且つ有効な量の局所麻酔剤を含んでもよい。局所麻酔剤の例としては、ベンゾカイン、リドカイン、ブピバカイン、クロルプロカイン、ジブカイン、エチドカイン、メピバカイン、テトラカイン、ジクロニン、ヘキシルカイン、プロカイン、コカイン、ケタミン、プラモキシン、フェノール、及び製薬上許容できるこれらの塩が挙げられる。
本発明の組成物は、日焼け活性物質を含んでもよい。存在する場合、組成物は、組成物の約0.1重量%〜約20重量%、更に好ましくは約2重量%〜約7重量%、最も好ましくは約3重量%〜約6重量%のジヒドロキシアセトンを人工の日焼け活性物質として含むのが好ましい。
本発明の組成物は美白剤を含んでもよい。使用する時、組成物は、好ましくは組成物の約0.1重量%〜約10重量%、より好ましくは約0.2重量%〜約5重量%、更に好ましくは約0.5重量%〜約2重量%の美白剤を含む。好適な美白剤としては、コウジ酸、アルブチン、トラネキサム酸、アスコルビン酸及びその誘導体、例えば、アスコルビン酸リン酸マグネシウム、アスコルビン酸リン酸ナトリウム、又はリン酸アスコルビルのその他の塩、アスコルビルグルコシドなどを含む、当該技術分野において既知のものが挙げられる。本明細書に用いるのに好適な他の美白剤物質としては、ウンデシルエノイルフェニルアラニン(SEPPIC製のセピホワイト(Sepiwhite)(登録商標))、アロエシン、アクチホワイト(Actiwhite)(登録商標)(コグニス(Cognis))、エンブリカ(登録商標)(Emblica)(??)及びアゼログリシナ(Azeloglicina)(??)が挙げられる。本明細書に用いるのに好適な美白剤としては、また、PCT出願第US95/07432号(1995年6月12日出願)に相当する同時係属の特許出願第08/479,935号(ヒルブランド(Hillebrand)の名において、1995年6月7日出願)、及びPCT出願第US95/02809号(1995年3月1日出願、1995年9月8日公開)に相当する同時係属の特許出願第08/390,152号(カーラL.クバルネス(Kalla L.Kvalnes)、ミッチェルA.デロング(Mitchell A.DeLong)、バートンJ.ブラッドベリ(Barton J.Bradbury)、カーチスB.モトレー(Curtis B.Motley)及びジョンD.カーター(John D.Carter)の名において、1995年2月24日出願)に記載されるものが挙げられる。
本発明の組成物は、抗菌又は抗カビ活性物質を含んでもよい。このような活性物質は、微生物を駆除し、微生物の発生を防止し、又は微生物の病原作用を防止し得る。安全且つ有効な量の抗菌又は抗カビ活性物質は、本発明の組成物に、好ましくは約0.001%〜約10%、更に好ましくは約0.01%〜約5%、最も好ましくは約0.05%〜約2%加えてもよい。
紫外線に曝されることによって、角質層の過度の鱗屑と組織変化を招き得る。したがって、本発明の組成物は、任意に日焼け止め活性物質を含有してもよい。本明細書で使用するとき、「日焼け止め活性物質」とは、日焼け止め剤及び物理的日焼け防止剤の両方を含む。好適な日焼け止め活性物質は、有機又は無機であってよい。
本発明の組成物は、湿潤剤、加湿剤、又は皮膚コンディショナーから成る群から選択されるコンディショニング剤を含んでもよい。これらの様々な物質を使用することができ、それぞれ、組成物の約0.01重量%〜約20重量%、更に好ましくは約0.1重量%〜約10重量%、最も好ましくは約0.5重量%〜約7重量%の濃度で存在し得る。これらの物質には、グアニジン;尿素;グリコール酸及びグリコール酸塩(例えば、アンモニウム及び四級アルキルアンモニウム);サリチル酸;乳酸及び乳酸塩(例えば、アンモニウム及び四級アルキルアンモニウム);様々な形態のうちのいずれかのアロエベラ(例えば、アロエベラジェル);ソルビトール、マンニトール、グリセロール、ヘキサントリオール、ブタントリオール、プロピレングリコール、ブチレングリコール、ヘキシレングリコールなどのようなポリヒドロキシ化合物;ポリエチレングリコール;糖類(例えば、メリビオース)及びデンプン;糖及びデンプン誘導体(例えば、アルコキシル化グルコース、フルクトース、スクロースなど);ヒアルロン酸;ラクトアミドモノエタノールアミン;アセトアミドモノエタノールアミン;並びにこれらの混合物が挙げられるが、これらに限定されない。また、本明細書で有用なのは、米国特許第4,976,953号(オール(Orr)ら、1990年12月11日発行)に記載されるプロポキシル化グリセロールである。
本発明の組成物は、好ましくは組成物の約0.1重量%〜約5重量%、更に好ましくは約0.1重量%〜約3重量%、最も好ましくは約0.25重量%〜約2重量%の1つ以上の濃厚剤を含むことができる。
非限定的な濃厚剤の種類は以下から成る群から選択されるものが挙げられる:
(i)カルボン酸ポリマー
これらのポリマーは、アクリル酸、置換アクリル酸、及びこれらのアクリル酸や置換アクリル酸の塩及びエステルに由来する1つ以上のモノマーを含有する架橋した化合物であるが、ここで架橋剤は2つ以上の炭素間二重結合を含有し、また多価アルコールに由来する。本発明で有用なポリマーは、米国特許第5,087,445号(ハフェイ(Haffey)ら、1992年2月11日発行);米国特許第4,509,949号(フアン(Huang)ら、1985年4月5日発行);米国特許第2,798,053号(ブラウン(Brown)、1957年年7月2日発行)において;及び「CTFA国際化粧品成分辞典(CTFA International Cosmetic Ingredient Dictionary)」第4版、1991年、12〜80頁において更に十分に記載されている。
本発明の組成物は、陽イオン性及び非イオン性ポリマーを含む、増粘剤又はゲル化剤として有用な架橋ポリアクリレートポリマーを任意に含むことができるが、陽イオン性ポリマーが一般に好ましい。有用な架橋非イオン性ポリアクリレートポリマー及び架橋陽イオン性ポリアクリレートポリマーの例は、米国特許第5,100,660号(ハウェ(Hawe)ら、1992年3月31日発行);米国特許第4,849,484号(ハード(Heard)、1989年7月18日発行);米国特許第4,835,206号(ファラー(Farrar)ら、1989年5月30日発行);米国特許第4,628,078号(グローバー(Glover)ら、1986年12月9日発行);米国特許第4,599,379号(フレッシャー(Flesher)ら、1986年7月8日発行);及び欧州特許第228,868号(ファラー(Farrar)ら、1987年7月15日公開)に記載されるものである。
本発明の組成物は、ポリアクリルアミドポリマー、特に置換分枝又は非分枝ポリマーを含む、非イオン性ポリアクリルアミドポリマーを任意に含むことができる。これらのポリアクリルアミドポリマーのうち最も好ましいのは、非イオン性ポリマーであるCTFA指定ポリアクリルアミド及びイソパラフィン及びラウレス7であり、商品名セピゲル(Sepigel)305としてセピック社(Seppic Corporation)(ニュージャージー州フェアフィールド(Fairfield))より市販されている。
多種多様な多糖類が本明細書で有用である。「多糖類」とは、繰り返す糖(即ち、炭水化物)単位の主鎖を含有するゲル化剤のことをいう。多糖類ゲル化剤の非限定的な例としては、セルロース、カルボキシメチルヒドロキシエチルセルロース、プロピオン酸カルボン酸セルロースアセテート、ヒドロキシエチルセルロース、ヒドロキシエチルエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルヒドロキシエチルセルロース、微結晶セルロース、セルロース硫酸ナトリウム、及びこれらの混合物から成る群から選択されるものが挙げられる。アルキル置換セルロースも本明細書において有用である。これらのポリマーでは、セルロースポリマーのヒドロキシ基は、ヒドロキシアルキル化(好ましくは、ヒドロキシエチル化又はヒドロキシプロピル化)して、ヒドロキシアルキル化セルロースを形成し、次いで更にC10〜C30直鎖又は分枝鎖アルキル基によって、エーテル結合を通じて修飾される。典型的には、これらのポリマーは、C10〜C30の直鎖又は分枝鎖アルコールとヒドロキシアルキルセルロースとのエーテルである。本明細書で有用なアルキル基の例としては、ステアリル、イソステアリル、ラウリル、ミリスチル、セチル、イソセチル、ココイル(即ち、ココヤシ油のアルコールに由来するアルキル基)、パルミチル、オレイル、リノレイル、リノレニル、リシノレイル、ベヘニル、及びこれらの混合物から成る群から選択されるものが挙げられる。アルキルヒドロキシアルキルセルロースエーテルの中でも好ましいのは、CTFA表記セチルヒドロキシエチルセルロースの物質であり、これはセチルアルコールとヒドロキシエチルセルロースとのエーテルである。この物質は、アクアロン社(Aqualon Corporation)(デラウェア州ウィルミントン)から、商品名ナトロゾル(Natrosol)(登録商標)CSプラス(Plus)として販売されている。
本明細書において有用なその他の増粘剤及びゲル化剤には、主として自然源より誘導される物質が挙げられる。これらのゲル化剤ゴムの非限定的な例としては、アカシア、寒天、アルギン、アルギン酸、アルギン酸アンモニウム、アミロペクチン、アルギン酸カルシウム、カラゲナンカルシウム、カルニチン、カラゲナン、デキストリン、ゼラチン、ゲランゴム、グアーガム、ヒドロキシプロピルトリモニウム塩化グアー、ヘクトライト、ヒアルロン酸、水酸化ケイ素、ヒドロキシプロピルキトサン、ヒドロキシプロピルグアー、カラヤゴム、ケルプ、イナゴマメゴム、納豆ゴム、アルギン酸カリウム、カラゲナンカリウム、アルギン酸プロピレングリコール、スクレロチンゴム、カルボキシメチルデキストランナトリウム、カラゲナンナトリウム、トラガカントゴム、キサンタンゴム、及びその混合物から成る群から選択される物質が挙げられる。
本発明の組成物は一般的には、局所用組成物を製造する技術分野において既知である従来の方法で調製される。このような方法は典型的には、加熱、冷却、真空適用などの有り又は無しで、各成分を1段階又はそれより多くの段階で混合して、比較的均一な状態にすることを伴う。組成物は好ましくは、安定性(物理的安定性、化学的安定性、光安定性)及び/又は活性物質(例えば、ヘキサミジン、糖アミン、ビタミンB3、レチニルプロピオネート、フィトステロール)の送給を最適化するように調製される。この最適化には、適切なpH(例えば、7未満)、活性剤と錯体になり、ひいては安定性又は送給に負の影響を与え得る物質の排除(例えば、汚染鉄の排除)、錯体形成を防止する手法(例えば、適切な分散剤又は二重区画包装)の使用、適切な光安定性の手法(例えば、日焼け止め剤/日焼け防止剤の組み込み、不透明包装の使用)の使用などを挙げてもよい。
本発明の組成物は、多数の哺乳類のケラチン組織状態の調整に有用である。ケラチン組織状態のそのような調整には、予防的及び治療的な調整が含まれる。より具体的には、こうした調整方法は、これらに限定されないが、ケラチン組織を厚くさせる(即ち、表皮及び/又は真皮及び/又は皮膚の皮下層並びに適用可能であれば爪及び毛幹のケラチン層の構築)、哺乳類の皮膚の萎縮を予防、抑制、及び/又は処置すること、哺乳類の唇、毛髪及び爪を軟らかくすること及び/又は滑らかにすること、哺乳類の皮膚のかゆみを予防、抑制、及び/又は処置すること、目の下の黒い隈及び/又は腫れた目が現れることを予防、抑制、及び/又は処置すること、哺乳類の皮膚の血色の悪さを予防、抑制、及び/又は処置すること、哺乳類の皮膚の弛み(即ち、グリケーション)を予防、抑制、及び/又は処置すること、哺乳類の皮膚の日焼け剥離、剥脱を予防及び/又は抑制すること、及び/又は代謝回転を増加すること、哺乳類の皮膚の毛穴の大きさを減少させること、哺乳類の皮膚の脂っぽい/テカテカした外観を調整すること、炎症後の色素沈着などの色素沈着を予防、抑制、及び/又は処置すること、哺乳類の皮膚上のクモの巣状血管及び/又は赤斑が現れることを予防、抑制、及び/又は処置すること、哺乳類の皮膚の細い線及びしわを予防、抑制、及び/又は処置すること、皮膚の乾燥(即ち、荒れ、鱗屑状の剥がれ、剥脱)を予防、抑制、及び/又は処置すること、並びに哺乳類の皮膚のセルライトが現れることを予防、抑制、及び/又は処置することを対象とする。
以下の構成成分から従来の方法によって潤いを与えるスキンクリーム/ローションを調製する。
好適な容器において、相Aの構成成分を一緒にし、好適な混合器(例えば、テクマー(Tekmar)RW20ZM)で混合して、攪拌しながら約70〜80℃の温度に加熱し、この温度を維持する。分離型の好適な容器において、相Bの構成成分を一緒にし、好適な混合器で混合して、攪拌しながら約70〜75℃に加熱し、この温度を維持する。相B混合物をその後相A混合物に加え、組合せたものが乳化するまで十分に混合する。相A及び相Bの構成成分のエマルションをその後約60℃に冷却し、その後相Cの構成成分を連続して混合しながらエマルションに加える。相A、B及びCの構成成分のエマルションを更にその後約40℃に冷却し、その後相Dの構成成分を混合しながらエマルションに加える。得られたエマルションは、次に好適な粉砕機(テクマー(Tekmar)T−25)を使用して約5分間又は生成物が均一になるまで粉砕する。
以下の構成成分から従来の方法によって潤いを与えるスキンクリーム/ローションを調製する。
**ゴールドシュミット化学社(Goldschmidt Chemical Corporation)から入手可能なエイビル(Abil)EM−97
***ダウ・コーニング社(Dow Corning Corp.)製シリコーンエラストマー分散液
好適な容器において、相Aの構成成分を好適な混合器(例えば、テクマー(Tekmar)製モデルRW20DZM)で混合し、全構成成分が溶解するまで混合し続ける。その後、相Bの構成成分を好適な容器で混和し、好適な粉砕機(例えば、テクマー(Tekmar)RW−20)を使用して約5分間粉砕する。相Cの構成成分を、その後相B混合物に混合しながら加える。その後、相Dの構成成分を相B及び相Cの混合物に加え、得られた相B、C及びDの構成成分の組合せを好適な混合器(例えばテクマー(Tekmar)RW−20)を使用して約1時間混合する。その後、相Aをゆっくりと相B、C及びDの混合物に混合しながら加える。得られた混合物をその後生成物が均一になるまで連続的に混合する。得られた生成物をその後適切な粉砕機(例えばテクマー(Tekmar)T−25)を使用して約5分間粉砕する。
潤いを与える水中シリコーン型漿液(serums)/ローションを、以下の成分から従来の方法により調製する。
2エンゲルハード(Engelhard)製の二酸化チタン及び酸化スズ被覆雲母の緑色干渉顔料
3エッカート(Eckart)製の二酸化チタン被覆雲母の赤色干渉顔料
好適な容器中で、水相成分を合わせ、均一になるまで混合する。別の好適な容器中で、シリコーン/油相成分を合わせ、均一になるまで混合する。シリコーン/油相を水相に加え、得られたエマルションを(例えば、テクマー(Tekmar)T−25で)粉砕する。増粘剤及び次に残りの成分を攪拌しながらエマルションに加える。組成物が均一になったら、生成物を好適な容器へ注ぐ。
(水中シリコーン型ムース)
2エッカート(Eckart)製の二酸化チタン被覆雲母の赤色干渉顔料
好適な容器中で、水相成分を合わせ、均一になるまで混合する。別の好適な容器中で、シリコーン/油相成分を合わせ、均一になるまで混合する。シリコーン/油相を水相に加え、得られたエマルションを(例えば、テクマー(Tekmar)T−25で)粉砕する。増粘剤及び次に残りの成分を攪拌しながらエマルションに加える。組成物が均一になったら、生成物を好適な容器へ注ぐ。生成物及び噴射剤をエアゾール容器に加える。次いで、エアゾール容器を密封する。
(水系スティック製剤)
手及び身体スキンケア用の潤いを与えるスキンクリーム/ローションを以下の成分から従来の方法により調製する。
Claims (1)
- スキンケア組成物であって、
a)ヘキサミジン及びその塩からなる群から選択されるヘキサミジン化合物と、
b)安全且つ有効な量のナイアシンアミド及びその塩からなる群から選択されるナイアシンアミド化合物と、並びに
c)前記ヘキサミジン化合物及び前記ナイアシンアミド化合物のための皮膚科学的に許容可能なキャリア、を含むスキンケア組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/379,252 US20040175347A1 (en) | 2003-03-04 | 2003-03-04 | Regulation of mammalian keratinous tissue using hexamidine compositions |
PCT/US2004/006499 WO2004078158A2 (en) | 2003-03-04 | 2004-03-04 | Regulation of mammalian keratinous tissue using hexamidine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006515329A JP2006515329A (ja) | 2006-05-25 |
JP4234137B2 true JP4234137B2 (ja) | 2009-03-04 |
Family
ID=32926642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005518889A Expired - Lifetime JP4234137B2 (ja) | 2003-03-04 | 2004-03-04 | ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20040175347A1 (ja) |
EP (2) | EP1603529B1 (ja) |
JP (1) | JP4234137B2 (ja) |
KR (2) | KR100825695B1 (ja) |
CN (1) | CN100421644C (ja) |
AU (1) | AU2004218346B2 (ja) |
BR (1) | BRPI0408062A (ja) |
CA (1) | CA2516501C (ja) |
HK (1) | HK1086738A1 (ja) |
MX (1) | MXPA05009392A (ja) |
WO (1) | WO2004078158A2 (ja) |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US20060062816A1 (en) * | 2001-10-01 | 2006-03-23 | Gatto Joseph A | Sanitary napkins with hydrophobic lotions |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
WO2004037225A2 (en) | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20040175347A1 (en) * | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20050255060A1 (en) * | 2004-05-10 | 2005-11-17 | Oblong John E | Personal care compositions and methods regulating mammalian hair growth |
US20050255059A1 (en) * | 2004-05-10 | 2005-11-17 | Oblong John E | Personal care compositions and methods regulating mammalian hair growth |
GB0422525D0 (en) * | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
JP2006117534A (ja) * | 2004-10-19 | 2006-05-11 | Kose Corp | 乳化化粧料 |
KR20070112289A (ko) * | 2005-03-16 | 2007-11-22 | 프로사이트 코포레이션 | 노화 또는 광손상된 피부를 예방하고 치료하기 위한 방법및 조성물 |
ATE527985T1 (de) * | 2005-03-23 | 2011-10-15 | Mary Kay Inc | Zusammensetzungen zur hautaufhellung |
US20080095732A1 (en) * | 2005-04-27 | 2008-04-24 | Rosemarie Osborne | Personal care compositions |
US20070020220A1 (en) | 2005-04-27 | 2007-01-25 | Procter & Gamble | Personal care compositions |
US9616011B2 (en) | 2005-04-27 | 2017-04-11 | The Procter & Gamble Company | Personal care compositions |
US20070020221A1 (en) * | 2005-05-17 | 2007-01-25 | Bissett Donald L | Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride |
US20060263321A1 (en) * | 2005-05-17 | 2006-11-23 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using personal care compositions comprising diethylhexyl syringylidene malonate |
US20060263309A1 (en) * | 2005-05-17 | 2006-11-23 | Bissett Donald L | Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin |
US20060263400A1 (en) * | 2005-05-17 | 2006-11-23 | Bissett Donald L | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
WO2007007255A2 (en) * | 2005-07-08 | 2007-01-18 | The Procter & Gamble Company | Personal care compositions and methods for the beautification of mammalian skin and hair |
US9089493B2 (en) * | 2005-09-16 | 2015-07-28 | The Procter & Gamble Company | Skin care composition |
US20070128137A1 (en) * | 2005-12-02 | 2007-06-07 | Naohisa Yoshimi | Water in oil emulsion compositions containing siloxane elastomers |
DE102006009850A1 (de) * | 2006-03-01 | 2007-09-06 | Beiersdorf Ag | Verwendung von Glycyrrhetinsäure und/oder Glycyrrhizin zur Herstellung kosmetischer Zubereitungen zur Bräunung der Haut |
US20080031833A1 (en) * | 2006-03-13 | 2008-02-07 | Oblong John E | Combined energy and topical composition application for regulating the condition of mammalian skin |
US20070274932A1 (en) * | 2006-05-15 | 2007-11-29 | The Procter & Gamble Company | Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers |
CN101442981A (zh) * | 2006-05-15 | 2009-05-27 | 宝洁公司 | 增强水溶性活性物质渗透的方法 |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
KR20120113765A (ko) * | 2007-01-16 | 2012-10-15 | 더 프록터 앤드 갬블 캄파니 | 화장 조성물 |
US8469621B2 (en) * | 2007-02-27 | 2013-06-25 | The Procter & Gamble Company | Personal care product having a solid personal care composition within a structure maintaining dispenser |
US20090017080A1 (en) * | 2007-03-15 | 2009-01-15 | Paul Robert Tanner | Personal care kit having skin care compositions with a readily perceptible difference |
US8029771B2 (en) | 2007-06-29 | 2011-10-04 | Mary Kay Inc. | Guar gum containing compounds |
US20090011035A1 (en) * | 2007-07-03 | 2009-01-08 | Joseph Michael Zukowski | Personal care composition |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US20090196836A1 (en) * | 2007-10-25 | 2009-08-06 | Paul Robert Tanner | Multi-Functional, Multi-Phase Skin Care Product |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8409154B2 (en) * | 2008-05-15 | 2013-04-02 | Wyeth | Method of delivering a skin benefit |
US8163298B2 (en) * | 2008-10-29 | 2012-04-24 | The Procter & Gamble Company | Aqueous gel having an alpha-hydroxy acid and suspended particulates |
US20100224205A1 (en) * | 2008-12-09 | 2010-09-09 | Shekhar Mitra | Device and methods for modifying keratinous surfaces |
JP5379244B2 (ja) | 2009-01-16 | 2013-12-25 | ザ プロクター アンド ギャンブル カンパニー | 角質表面を改変するための装置及び方法 |
WO2010085532A2 (en) | 2009-01-22 | 2010-07-29 | The Procter & Gamble Company | Skin-care composition comprising dill extract |
US9676696B2 (en) * | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
ES2322122B1 (es) * | 2009-02-10 | 2010-07-16 | Laboratorios Starga S.L. | Composicion cosmetica para el cuidado y reparacion de telangiectasias. |
US20100227011A1 (en) * | 2009-02-24 | 2010-09-09 | Dennis Eugene Kuhlman | Regulation of mammalian keratinous tissue using personal-care compositions comprising a turmerone compound |
JP6130992B2 (ja) * | 2009-02-25 | 2017-05-17 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | 局所用フォーム組成物 |
EP2408421A2 (en) * | 2009-03-20 | 2012-01-25 | The Procter & Gamble Company | Personal-care composition comprising oil-soluble solid sunscreens |
JP2012521356A (ja) * | 2009-03-20 | 2012-09-13 | ザ プロクター アンド ギャンブル カンパニー | 炭化水素ワックスと極性油とを含むパーソナルケア組成物 |
WO2010111267A2 (en) | 2009-03-23 | 2010-09-30 | The Procter & Gamble Company | Personal-care composition comprising a cationic active |
WO2010111266A2 (en) | 2009-03-23 | 2010-09-30 | The Procter & Gamble Company | Personal-care composition comprising a cationic active |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
US20100322983A1 (en) * | 2009-06-22 | 2010-12-23 | Susan Adair Griffiths-Brophy | Personal-Care Composition |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US20110033512A1 (en) | 2009-08-10 | 2011-02-10 | Laurie Ellen Breyfogle | Personal care composition with improved spreadability |
KR101443927B1 (ko) * | 2009-08-20 | 2014-09-25 | (주)아모레퍼시픽 | 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물 |
MX359879B (es) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Composiciones tópicas de tetraciclina. |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8933131B2 (en) | 2010-01-12 | 2015-01-13 | The Procter & Gamble Company | Intermediates and surfactants useful in household cleaning and personal care compositions, and methods of making the same |
MX2012011475A (es) | 2010-04-01 | 2012-11-16 | Procter & Gamble | Composiciones que comprenden organosiliconas. |
US20110269657A1 (en) | 2010-04-28 | 2011-11-03 | Jiten Odhavji Dihora | Delivery particles |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
US20120172281A1 (en) | 2010-07-15 | 2012-07-05 | Jeffrey John Scheibel | Detergent compositions comprising microbially produced fatty alcohols and derivatives thereof |
EP2593080A2 (en) | 2010-07-15 | 2013-05-22 | The Procter and Gamble Company | Method of cleansing hair |
JP2012520349A (ja) | 2010-07-22 | 2012-09-06 | ザ プロクター アンド ギャンブル カンパニー | フトコンブの抽出物を用いた色素過剰スポットの外観を改善するための方法 |
EP2595600A1 (en) | 2010-07-22 | 2013-05-29 | The Procter and Gamble Company | Methods for inhibiting tyrosinase using an extract of laminaria saccharina |
JP2012519735A (ja) | 2010-07-22 | 2012-08-30 | ザ プロクター アンド ギャンブル カンパニー | 角化細胞のpar2活性化を阻害するための組成物及び方法 |
WO2012011905A1 (en) | 2010-07-22 | 2012-01-26 | The Procter & Gamble Company | Methods for improving the appearance of hyperpigmented spot(s) with multiple actives |
WO2012011907A1 (en) | 2010-07-22 | 2012-01-26 | The Procter & Gamble Company | Laminaria saccharina extract and vitamin b3 as whitening agents |
US20120201768A1 (en) | 2010-09-10 | 2012-08-09 | Cheri Lynn Swanson | Cosmetic compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation |
JP5938803B2 (ja) | 2010-09-10 | 2016-06-22 | アイエスピー インヴェストメンツ インコーポレイテッドIsp Investments Inc. | イチジク漿液画分を含む生理活性組成物および皮膚の色素沈着過剰の外観を低減するための方法 |
WO2012068195A1 (en) | 2010-11-18 | 2012-05-24 | The Procter & Gamble Company | Cosmetic compositions based on a n-acyl amino acid compound and hexyldecanol |
EP2640347B1 (en) | 2010-11-19 | 2018-03-21 | The Procter and Gamble Company | Improvement of the appearance of fine lines and wrinkles |
US8524204B2 (en) | 2010-11-19 | 2013-09-03 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting or reducing trypsin activity |
EP2640345B1 (en) * | 2010-11-19 | 2018-03-28 | The Procter and Gamble Company | Improvement of the appearance of facial pores |
DE102010054149A1 (de) * | 2010-12-10 | 2012-06-14 | Merck Patent Gmbh | 2-Pyrone |
DE102010063894A1 (de) * | 2010-12-22 | 2012-06-28 | Beiersdorf Ag | Kosmetische oder dermatologische Lichtschutzzubereitungen mit hohem Silikonölgehalt umfassend eine Kombination aus Polyacrylat- und Polyacrylamidverdicker |
JP5864615B2 (ja) | 2011-01-25 | 2016-02-17 | ザ プロクター アンド ギャンブルカンパニー | リポソーム及びそれを含むパーソナルケア組成物 |
US8673372B2 (en) | 2011-02-22 | 2014-03-18 | The Procter & Gamble Company | Methods for improving the appearance of hyperpigmented skin using a synergistic composition comprising banyan tree, lotus, and clover serum fractions |
WO2012116077A2 (en) | 2011-02-22 | 2012-08-30 | The Procter & Gamble Company | Methods for improving the appearance of aging skin using a composition comprising banyan tree, lotus, and clover serum fractions |
ES2616928T3 (es) | 2011-02-22 | 2017-06-14 | Isp Investments Inc. | Composición cosmética que comprende fracciones de suero de baniano, de loto y de trébol |
CA2827736A1 (en) | 2011-02-22 | 2012-08-30 | Akzo Nobel Chemicals International B.V. | Composition comprising banyan tree, lotus, and clover serum fractions (hyperpigmentation) |
JP6283607B2 (ja) | 2011-04-07 | 2018-02-21 | ザ プロクター アンド ギャンブル カンパニー | ポリアクリレートマイクロカプセルの堆積が増大されたパーソナルクレンジング組成物 |
EP2694016B1 (en) | 2011-04-07 | 2017-05-24 | The Procter and Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
EP2694031B1 (en) | 2011-04-07 | 2015-07-08 | The Procter and Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
CN102309435A (zh) * | 2011-05-19 | 2012-01-11 | 大连九羊食品有限公司 | 一种含有羊乳脂的乳液及其制备方法 |
DE102011078092A1 (de) * | 2011-06-27 | 2012-12-27 | Beiersdorf Ag | Kosmetische Wasser-in-Silikonöl-Emulsion |
US20130011347A1 (en) | 2011-07-07 | 2013-01-10 | Paul Robert Tanner | Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active |
US9192552B2 (en) | 2011-07-07 | 2015-11-24 | The Procter & Gamble Company | Personal care compositions with improved solubility of a solid UV active |
GB201115660D0 (en) * | 2011-09-09 | 2011-10-26 | Celesscence Internat Ltd | An aqueous formulation for dispensing as a spray polymeric microcapsules containing at least one active ingredient |
JP6155492B2 (ja) | 2011-09-26 | 2017-07-05 | ディーエスエム アイピー アセッツ ビー.ブイ. | 新規組成物 |
US9283161B2 (en) | 2011-09-26 | 2016-03-15 | Dsm Ip Assets B.V. | Aqueous cosmetic compositions containing resveratrol solubilized in a liquid phosphate ester surfactant |
JP5877456B2 (ja) | 2011-12-22 | 2016-03-08 | アイエスピー インヴェストメンツ インコーポレイテッドIsp Investments Inc. | 毛髪抗老化活性を有する生物活性組成物 |
CN104053430A (zh) | 2011-12-22 | 2014-09-17 | 宝洁公司 | 改善老化毛发外观的组合物和方法 |
US10172784B2 (en) | 2011-12-22 | 2019-01-08 | Isp Investments Llc | Bioactive compositons having skin anti aging activity |
JP5860166B2 (ja) | 2011-12-22 | 2016-02-16 | ザ プロクター アンド ギャンブルカンパニー | 皮膚の処置のための組成物及び方法 |
CN104144676B (zh) | 2012-03-01 | 2017-12-12 | 宝洁公司 | 包含紫外线复合材料的防晒剂组合物 |
US9549891B2 (en) | 2012-03-19 | 2017-01-24 | The Procter & Gamble Company | Superabsorbent polymers and sunscreen actives for use in skin care compositions |
CN104244923A (zh) | 2012-04-20 | 2014-12-24 | 宝洁公司 | 用于改善面部毛孔外观的组合物和方法 |
WO2013184908A2 (en) | 2012-06-06 | 2013-12-12 | The Procter & Gamble Company | Systems and methods for identifying cosmetic agents for hair/scalp care compositions |
EP2861207A2 (en) | 2012-06-18 | 2015-04-22 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
US20140178314A1 (en) | 2012-12-19 | 2014-06-26 | The Procter & Gamble Company | Compositions and/or articles with improved solubility of a solid active |
US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
ES2652301T3 (es) | 2013-03-05 | 2018-02-01 | The Procter & Gamble Company | Composiciones tensioactivas mixtas de amida de base azucarada |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
EP2996775A1 (en) | 2013-05-16 | 2016-03-23 | The Procter & Gamble Company | Hair thickening compositions and methods of use |
US9005674B1 (en) | 2013-07-01 | 2015-04-14 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
US10543165B2 (en) | 2013-07-16 | 2020-01-28 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
US20150023897A1 (en) | 2013-07-22 | 2015-01-22 | The Procter & Gamble Company | Method of protecting skin from oxidative stress |
CN106456005B (zh) | 2014-06-13 | 2020-12-08 | 宝洁公司 | 用于使角质表面改性的设备和方法 |
US10518291B2 (en) | 2014-06-13 | 2019-12-31 | The Procter & Gamble Company | Device and methods for modifying surfaces |
CN106456055B (zh) | 2014-06-13 | 2020-04-14 | 宝洁公司 | 用于使角质表面改性的设备和方法 |
CN106457848B (zh) | 2014-06-13 | 2018-11-09 | 宝洁公司 | 用于使角质表面改性的设备和方法 |
US10156036B2 (en) | 2014-06-13 | 2018-12-18 | The Procter & Gamble Company | Device and methods for applying compositions to fabric surfaces |
WO2015191830A2 (en) | 2014-06-13 | 2015-12-17 | The Procter & Gamble Company | Treatment compositions, apparatus and methods for modifying keratinous surfaces |
CN106457288B (zh) | 2014-06-13 | 2021-05-11 | 宝洁公司 | 改变角质表面的设备和方法 |
US20160114349A1 (en) | 2014-06-13 | 2016-04-28 | The Procter & Gamble Company | Device and methods for depositing materials on hard surfaces |
CA2949123C (en) | 2014-06-13 | 2019-05-14 | The Procter & Gamble Company | Cartridges for the deposition of treatment compositions on keratinous surfaces |
US9955769B2 (en) | 2014-07-25 | 2018-05-01 | The Procter & Gamble Company | Applicator heads for handheld treatment apparatus for modifying keratinous surfaces |
US10314378B2 (en) | 2014-07-25 | 2019-06-11 | The Procter & Gamble Company | Cartridge assembly for a dispensing device |
US11083880B2 (en) | 2014-07-25 | 2021-08-10 | The Procter & Gamble Company | Angled cartridge assembly for a dispensing device |
US9949552B2 (en) | 2014-07-25 | 2018-04-24 | The Procter & Gamble Company | Handheld treatment apparatus for modifying keratinous surfaces |
US10188193B2 (en) | 2014-07-25 | 2019-01-29 | The Procter & Gamble Company | Applicator heads for handheld treatment apparatus for modifying keratinous surfaces |
EP3256561A1 (en) * | 2015-02-09 | 2017-12-20 | The Procter and Gamble Company | Cleaning and/or treatment compositions |
WO2016178944A1 (en) | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
EP3288530A1 (en) | 2015-05-01 | 2018-03-07 | The Procter and Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
EP3302716B1 (en) | 2015-06-08 | 2020-10-14 | The Procter and Gamble Company | Methods for identifying circadian rhythm-dependent cosmetic agents for skin care compositions |
US9949547B2 (en) | 2015-06-11 | 2018-04-24 | The Procter & Gamble Company | Cartridges for use in an apparatus for modifying keratinous surfaces |
US11116302B2 (en) | 2015-06-11 | 2021-09-14 | The Procter & Gamble Company | Apparatus and methods for modifying keratinous surfaces |
US9962532B2 (en) | 2015-06-11 | 2018-05-08 | The Procter & Gamble Company | Cartridges for use in an apparatus for modifying keratinous surfaces |
EP3313534A1 (en) | 2015-06-29 | 2018-05-02 | The Procter and Gamble Company | Superabsorbent polymers and starch powders for use in skin care compositions |
US20160374908A1 (en) | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Skin care composition and methods of using the same |
WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
WO2017004100A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Encapsulated particles comprising nicotinamide riboside |
US10166799B2 (en) | 2015-12-07 | 2019-01-01 | The Procter & Gamble Company | Service stations for handheld fluid jet apparatuses |
US10391042B2 (en) | 2015-12-07 | 2019-08-27 | The Procter & Gamble Company | Treatment compositions, apparatus and methods for modifying keratinous surfaces |
US9616668B1 (en) | 2015-12-07 | 2017-04-11 | The Procter & Gamble Company | Servicing cassettes for handheld fluid jet apparatuses for use in modifying surfaces |
BR112018013757B1 (pt) | 2016-01-11 | 2021-11-09 | The Procter & Gamble Company | Método para o tratamento de uma condição de pele e composições para o mesmo |
US20170296456A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Products and methods for treating periorbital dyschromia |
US20170296458A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Cosmetic composition |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
US20170296460A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
US20170296459A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
US20170296457A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Products and methods for treating periorbital dyschromia |
US11035851B2 (en) | 2016-05-09 | 2021-06-15 | The Procter & Gamble Company | Method of identifying cosmetic agents for moisturizing skin |
MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
US20180221256A1 (en) | 2017-02-06 | 2018-08-09 | The Procter & Gamble Company | Personal Care Composition |
US11090238B2 (en) | 2017-06-16 | 2021-08-17 | The Procter & Gamble Company | Array of cosmetic compositions for camouflaging tonal imperfections |
JP6931404B2 (ja) | 2017-06-16 | 2021-09-01 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 可聴フィードバックを有するパーソナルケアデバイス |
BR112019026855B1 (pt) | 2017-06-16 | 2023-01-24 | The Procter & Gamble Company | Método colorimétrico de maquiagem assistido por computador para camuflar anormalidades na cor da pele |
CN114788791A (zh) | 2017-06-23 | 2022-07-26 | 宝洁公司 | 用于改善皮肤外观的组合物和方法 |
WO2019226722A1 (en) | 2018-05-22 | 2019-11-28 | The Procter & Gamble Company | System and method for identifying connections between perturbagens and genes associated with a skin condition |
US10980851B2 (en) | 2018-06-08 | 2021-04-20 | The Procter & Gamble Company | Topical skincare compositions comprising Centella asiatica selected triterpenes |
US10874600B2 (en) | 2018-06-18 | 2020-12-29 | The Procter & Gamble Company | Method for degrading bilirubin in skin |
KR20210008853A (ko) | 2018-06-29 | 2021-01-25 | 더 프록터 앤드 갬블 캄파니 | 이중상 제품 분배기 |
KR20210008860A (ko) * | 2018-06-29 | 2021-01-25 | 더 프록터 앤드 갬블 캄파니 | 이중상 제품 |
JP2021528443A (ja) | 2018-06-29 | 2021-10-21 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 二相製品 |
EP3817717A1 (en) | 2018-07-03 | 2021-05-12 | The Procter & Gamble Company | Method of treating a skin condition |
JP7546341B2 (ja) * | 2018-07-24 | 2024-09-06 | ロート製薬株式会社 | コレステロール及び/又はフィトステロールを含有する外用組成物 |
EP3905920B1 (en) | 2019-01-03 | 2022-11-02 | The Procter & Gamble Company | Personalized skin care system |
WO2020142607A2 (en) | 2019-01-04 | 2020-07-09 | Beiersdorf Ag | Antioxidant compositions and uses thereof |
US20200405621A1 (en) | 2019-06-28 | 2020-12-31 | The Procter & Gamble Company | Skin Care Composition |
US11786451B2 (en) | 2019-06-28 | 2023-10-17 | The Procter & Gamble Company | Skin care composition |
CN113924108B (zh) | 2019-07-15 | 2023-01-17 | 宝洁公司 | 包含积雪草的局部用护肤组合物 |
CN114269945B (zh) | 2019-08-23 | 2024-07-19 | 宝洁公司 | 鉴定纤维化过程的调节物的方法 |
CN115003274B (zh) | 2020-01-24 | 2024-06-18 | 宝洁公司 | 护肤组合物 |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
WO2022132689A1 (en) | 2020-12-14 | 2022-06-23 | The Procter & Gamble Company | Stable skin care emulsion and methods of using the same |
EP4259068A1 (en) | 2020-12-14 | 2023-10-18 | The Procter & Gamble Company | Method of manufacturing cosmetic compositions comprising sucrose esters and solvents |
US12036302B2 (en) | 2020-12-14 | 2024-07-16 | The Procter & Gamble Company | Method of treating oxidative stress in skin and compositions therefor |
CN116583264A (zh) | 2020-12-14 | 2023-08-11 | 宝洁公司 | 包含蔗糖酯和溶剂的化妆品组合物 |
US11571378B2 (en) | 2021-01-22 | 2023-02-07 | The Procter & Gamble Company | Skin care composition and method of using the same |
US11771637B2 (en) | 2021-01-22 | 2023-10-03 | The Procter & Gamble Company | Skin care composition and method of using the same |
US20220378679A1 (en) | 2021-05-30 | 2022-12-01 | The Procter & Gamble Company | Cosmetic product comprising a cosmetic composition contained in an applicator |
US20230137149A1 (en) | 2021-11-03 | 2023-05-04 | The Procter & Gamble Company | Cosmetic product comprising oil discontinuous phase and method of use thereof |
WO2023081671A1 (en) | 2021-11-03 | 2023-05-11 | The Procter & Gamble Company | Cosmetic composition comprising oil discontinuous phase |
WO2023097322A2 (en) | 2021-11-29 | 2023-06-01 | The Procter & Gamble Company | Skin care composition |
US20230165767A1 (en) | 2021-11-29 | 2023-06-01 | The Procter & Gamble Company | Skin care composition |
EP4440538A1 (en) | 2021-11-29 | 2024-10-09 | The Procter & Gamble Company | Method of improving the appearance of skin |
CN118284351A (zh) | 2021-12-03 | 2024-07-02 | 宝洁公司 | 具有可听反馈的个人护理装置 |
US20230190587A1 (en) | 2021-12-21 | 2023-06-22 | The Procter & Gamble Company | Cosmetic composition comprising sucrose ester and lauroyl lysine |
WO2023122465A2 (en) | 2021-12-21 | 2023-06-29 | The Procter & Gamble Company | Cosmetic composition comprising mica and lauroyl lysine |
WO2023122467A1 (en) | 2021-12-21 | 2023-06-29 | The Procter & Gamble Company | Cosmetic composition comprising vitamin b3 compound and lauroyl lysine |
US20230233440A1 (en) | 2022-01-24 | 2023-07-27 | The Procter & Gamble Company | Skin care serum containing sodium hyaluronate |
US20230233441A1 (en) | 2022-01-24 | 2023-07-27 | The Procter & Gamble Company | Skin care composition containing sodium hyaluronate and method of making the same |
US20230248798A1 (en) | 2022-02-10 | 2023-08-10 | The Procter & Gamble Company | Topical skin care composition |
IT202200004574A1 (it) | 2022-03-10 | 2023-09-10 | Sergio Ammendola | Nanoparticelle di N-acetilglucosammina e loro applicazioni |
US20230404897A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Skin care emulsion composition with clean polymers and emulsifiers |
US20230404898A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Skin care composition with clean polymer |
WO2023245098A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Topical skin care composition |
WO2024073219A1 (en) | 2022-09-28 | 2024-04-04 | The Procter & Gamble Company | Stable skin care compositions containing a retinoid |
US20240139091A1 (en) | 2022-10-12 | 2024-05-02 | The Procter & Gamble Company | Cosmetic composition comprising polyacrylate crosspolymer-6, and silica and/or lauroyl lysine |
US20240139084A1 (en) | 2022-10-12 | 2024-05-02 | The Procter & Gamble Company | Cosmetic composition comprising silica and lauroyl lysine |
US20240139090A1 (en) | 2022-10-12 | 2024-05-02 | The Procter & Gamble Company | Cosmetic composition comprising polyacrylate crosspolymer-6 and high hlb nonionic surfactant |
US20240325288A1 (en) | 2023-03-28 | 2024-10-03 | The Procter & Gamble Company | Cleansing balm |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1992246A (en) * | 1933-10-11 | 1935-02-26 | Harold L Smith | Electrical circuit |
US2438091A (en) | 1943-09-06 | 1948-03-16 | American Cyanamid Co | Aspartic acid esters and their preparation |
US2528378A (en) | 1947-09-20 | 1950-10-31 | John J Mccabe Jr | Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same |
US2658072A (en) | 1951-05-17 | 1953-11-03 | Monsanto Chemicals | Process of preparing amine sulfonates and products obtained thereof |
US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US2831854A (en) | 1955-05-24 | 1958-04-22 | Procter & Gamble | Method for preparing fatty esters of non-reducing oligosaccharides in the presence of an amide |
US3155591A (en) | 1961-12-06 | 1964-11-03 | Witco Chemical Corp | Hair rinse compostions of polyoxypropylene quaternary ammonium compounds |
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
DE2350315C2 (de) * | 1973-10-06 | 1984-01-12 | Johnson & Johnson GmbH, 4000 Düsseldorf | Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung |
US3963699A (en) | 1974-01-10 | 1976-06-15 | The Procter & Gamble Company | Synthesis of higher polyol fatty acid polyesters |
US3959461A (en) | 1974-05-28 | 1976-05-25 | The United States Of America As Represented By The Secretary Of Agriculture | Hair cream rinse formulations containing quaternary ammonium salts |
US3929678A (en) | 1974-08-01 | 1975-12-30 | Procter & Gamble | Detergent composition having enhanced particulate soil removal performance |
US4005196A (en) | 1976-02-12 | 1977-01-25 | The Procter & Gamble Company | Vitaminized compositions for treating hypercholesterolemia |
US4005195A (en) | 1976-02-12 | 1977-01-25 | The Procter & Gamble Company | Compositions for treating hypercholesterolemia |
US4120948A (en) * | 1976-11-29 | 1978-10-17 | The Procter & Gamble Company | Two phase antiperspirant compositions |
US4202879A (en) * | 1977-07-18 | 1980-05-13 | The Procter & Gamble Company | Three phase antiperspirant stick |
US4387090A (en) | 1980-12-22 | 1983-06-07 | The Procter & Gamble Company | Hair conditioning compositions |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
EP0093186B1 (en) * | 1982-05-03 | 1986-07-09 | Richardson Vicks Limited | Pharmaceutical preparation for the topical treatment of acne |
US4505925A (en) * | 1983-05-20 | 1985-03-19 | Warner-Lambert Company | N,N-diethyl-5-methyl-2H-1-benzothiopyrano-4,3,2-cd-indazole-2-ethanamine compositions and methods for their use |
US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
US4517360A (en) | 1983-06-23 | 1985-05-14 | The Procter & Gamble Company | Synthesis of higher polyol fatty acid polyesters using carbonate catalysts |
US4518772A (en) | 1983-06-23 | 1985-05-21 | The Proctor & Gamble Company | Synthesis of higher polyol fatty acid polyesters using high soap:polyol ratios |
GB8401206D0 (en) | 1984-01-17 | 1984-02-22 | Allied Colloids Ltd | Polymers and aqueous solutions |
GB8414950D0 (en) | 1984-06-12 | 1984-07-18 | Allied Colloids Ltd | Cationic polyelectrolytes |
US4559054A (en) * | 1984-08-09 | 1985-12-17 | Research Corporation | Rate-controlled drug release system |
US4557853A (en) | 1984-08-24 | 1985-12-10 | The Procter & Gamble Company | Skin cleansing compositions containing alkaline earth metal carbonates as skin feel agents |
US5151210A (en) | 1985-07-25 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
US4677120A (en) | 1985-07-31 | 1987-06-30 | Molecular Design International | Topical prodrugs for treatment of acne and skin diseases |
GB8531118D0 (en) | 1985-12-18 | 1986-01-29 | Allied Colloids Ltd | Copolymers |
US4835148A (en) | 1986-02-24 | 1989-05-30 | The Procter & Gamble Co. | Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents |
GB8622797D0 (en) | 1986-09-22 | 1986-10-29 | Allied Colloids Ltd | Polymeric particles |
ES2061508T3 (es) | 1986-10-01 | 1994-12-16 | Allied Colloids Ltd | Composiciones polimericas solubles en agua. |
US5143722B1 (en) * | 1986-12-19 | 1999-08-24 | Revlon Consumer Prod Corp | Cosmetic makeup compositions comprising water-in-oil emulsions containing pigment |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US4976953A (en) | 1987-03-06 | 1990-12-11 | The Procter & Gamble Company | Skin conditioning/cleansing compositions containing propoxylated glycerol derivatives |
US4960764A (en) | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
US4797300A (en) | 1987-04-10 | 1989-01-10 | The Procter & Gamble Company | Compositions containing novel solid, nondigestible, fat-like compounds |
US4781917A (en) * | 1987-06-26 | 1988-11-01 | The Proctor & Gamble Company | Antiperspirant gel stick |
USRE34075E (en) | 1987-06-29 | 1992-09-22 | Molecular Design International, Inc. | Dermal uses of trans-retinoids for the treatment of cancer |
US4885311A (en) | 1987-06-29 | 1989-12-05 | Molecular Design International | Topical transretinoids for treatment of acne and skin diseases |
US5124356A (en) | 1987-06-29 | 1992-06-23 | Molecular Design International, Inc. | Dermal uses of trans-retinoids for the treatment of photoaging |
EP0496433B1 (en) | 1987-10-22 | 1999-03-24 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
US4847071A (en) | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
US5151209A (en) | 1987-11-19 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
US4816261A (en) * | 1987-11-20 | 1989-03-28 | The Procter & Gamble Company | Deodorant gel stick |
JP2573006B2 (ja) * | 1987-12-17 | 1997-01-16 | 富士薬品工業株式会社 | 新規なヒドロキサム酸誘導体 |
EP0330369A1 (en) | 1988-02-16 | 1989-08-30 | Richardson-Vicks, Inc. | Skin conditioning composition |
US5049584A (en) | 1988-12-14 | 1991-09-17 | Molecular Design International | Dermal uses of cis-retinoids for the treatment of cancer |
JPH0660286B2 (ja) * | 1989-02-15 | 1994-08-10 | 信越化学工業株式会社 | 油性ペースト組成物 |
US5019375A (en) * | 1989-03-14 | 1991-05-28 | The Procter & Gamble Company | Low residue antiperspirant creams |
GB8909095D0 (en) | 1989-04-21 | 1989-06-07 | Allied Colloids Ltd | Thickened aqueous compositions |
US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
US5011681A (en) | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
FR2653013B1 (fr) * | 1989-10-13 | 1992-01-10 | Oreal | Procede de preparation d'une solution aqueuse effervescente ayant une action emolliente sur la cuticule des ongles, composition pour la mise en óoeuvre dudit procede et traitement cosmetique correspondant. |
US5093109A (en) * | 1990-04-04 | 1992-03-03 | Chanel, Inc. | Cosmetic composition |
US5120532A (en) | 1990-04-06 | 1992-06-09 | The Procter & Gamble Company | Hair styling shampoos |
WO1991016035A1 (en) | 1990-04-26 | 1991-10-31 | The Procter & Gamble Company | Chelator compositions comprising alpha-diamine compounds |
US5306514A (en) * | 1990-04-26 | 1994-04-26 | The Procter & Gamble Company | Solid, nondigestible, fat-like compounds and food compositions containing same |
US5306516A (en) | 1990-04-26 | 1994-04-26 | The Procter & Gamble Company | Shortening compositions containing polyol fatty acid polyesters |
US5306515A (en) | 1990-04-26 | 1994-04-26 | The Procter & Gamble Company | Reduced calorie pourable shortening, cooking oils, salad oils or like compositions |
DE69133277T2 (de) | 1990-04-26 | 2004-04-08 | The Procter & Gamble Company, Cincinnati | Chelat-zubereitungen, die oximverbindungen enthalten |
US5073372A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5413781A (en) * | 1991-01-17 | 1995-05-09 | Dow Corning Corporation | Alkylmethylsiloxanes for skin care |
EP0545002A1 (en) * | 1991-11-21 | 1993-06-09 | Kose Corporation | Silicone polymer, paste-like composition and water-in-oil type cosmetic composition comprising the same |
DE69310518T2 (de) * | 1992-07-28 | 1997-10-02 | Procter & Gamble | Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält |
FR2699818B1 (fr) | 1992-12-24 | 1995-02-03 | Oreal | Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko. |
FR2708466B1 (fr) * | 1993-06-30 | 1995-10-27 | Lvmh Rech | Utilisation d'un extrait de champignons Poria cocos Wolf pour la préparation d'une composition cosmétique ou pharmaceutique, notamment dermatologique pour le traitement de l'acné ou des peaux grasses. |
US5681852A (en) | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
CA2175581C (en) | 1993-11-12 | 1999-12-14 | Donald Lynn Bissett | Desquamation compositions containing salicylic acid and zwitterionic compounds |
US6238682B1 (en) * | 1993-12-13 | 2001-05-29 | The Procter & Gamble Company | Anhydrous skin lotions having antimicrobial components for application to tissue paper products which mitigate the potential for skin irritation |
FR2714602B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
US6068834A (en) * | 1994-03-04 | 2000-05-30 | The Procter & Gamble Company | Skin lightening compositions |
US5547677A (en) * | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
DE69526350T2 (de) | 1994-07-01 | 2003-03-13 | Textile Res Inst Inc | Abschuppungs-zusammensetzung |
US5599525A (en) * | 1994-11-14 | 1997-02-04 | Colgate Palmolive Company | Stabilized dentifrice compositions containing reactive ingredients |
JPH08217536A (ja) | 1995-02-14 | 1996-08-27 | Tdk Corp | 正の抵抗温度係数を有する半導体磁器組成物及びその製造方法 |
US6060547A (en) * | 1995-04-28 | 2000-05-09 | The Proctor & Gamble Company | Film forming foundation |
WO1997001313A2 (en) | 1995-06-29 | 1997-01-16 | The Procter & Gamble Company | Heat cells |
US5607980A (en) | 1995-07-24 | 1997-03-04 | The Procter & Gamble Company | Topical compositions having improved skin feel |
US5725845A (en) * | 1995-11-03 | 1998-03-10 | Revlon Consumer Products Corporation | Transfer resistant cosmetic stick compositions with semi-matte finish |
US5939082A (en) * | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
US5654362A (en) * | 1996-03-20 | 1997-08-05 | Dow Corning Corporation | Silicone oils and solvents thickened by silicone elastomers |
CA2251790C (en) | 1996-04-23 | 2003-10-21 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
US5760116A (en) * | 1996-09-05 | 1998-06-02 | General Electric Company | Elastomer gels containing volatile, low molecular weight silicones |
IT1288257B1 (it) * | 1996-11-29 | 1998-09-11 | Paoli Ambrosi Gianfranco De | Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico |
US5811487A (en) * | 1996-12-16 | 1998-09-22 | Dow Corning Corporation | Thickening silicones with elastomeric silicone polyethers |
US5750096A (en) * | 1996-12-20 | 1998-05-12 | The Procter & Gamble Company | Low residue antiperspirant gel-solid stick compositions containing select gellants |
FR2759583B1 (fr) * | 1997-02-17 | 1999-12-10 | Oreal | Composition antisolaire contenant un organopolysiloxane elastomerique solide |
WO1999047118A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions for regulating skin appearance |
AU5104499A (en) * | 1998-07-16 | 2000-02-07 | Asten, Inc. | Soft-faced dryer fabric |
EP1105117A1 (en) * | 1998-08-17 | 2001-06-13 | Evgeny Vladimirovich Soloviev | Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum |
US6207596B1 (en) * | 1998-11-09 | 2001-03-27 | The Procter & Gamble Company | Disposable premoistened wipe containing an antimicrobial protease inhibitor |
US6344218B1 (en) * | 1998-11-23 | 2002-02-05 | The Procter & Gamble Company | Skin deodorizing and santizing compositions |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US6284802B1 (en) * | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
US6444647B1 (en) * | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
MXPA01011801A (es) * | 1999-05-17 | 2002-04-24 | Procter & Gamble | Metodos para regular la condicion de tejido queratinoso de mamifero mediante la aplicacion topica de composiciones de fitoesterol. |
US6187327B1 (en) * | 1999-05-19 | 2001-02-13 | Kevin Stack | Antimicrobial sanitizing lotion with skin protection properties |
US6570054B1 (en) * | 1999-05-21 | 2003-05-27 | The Procter & Gamble Company | Absorbent article having a stable skin care composition |
EP1178844B1 (en) * | 1999-05-21 | 2005-10-26 | The Procter & Gamble Company | Absorbent article having a skin care composition |
US6503944B1 (en) * | 1999-05-26 | 2003-01-07 | The Andrew Jergens Company | Anhydrous skin care composition |
FR2796309B1 (fr) * | 1999-07-12 | 2002-04-19 | Oreal | Composition solide et ses utilisations notamment cosmetiques |
US6153209A (en) * | 1999-09-28 | 2000-11-28 | The Procter & Gamble Company | Article having a transferable breathable skin care composition thereon |
KR20020059450A (ko) * | 1999-12-21 | 2002-07-12 | 데이비드 엠 모이어 | 구멍이 형성된 적층 편물을 포함하는 일회용 제품 |
FR2807320B1 (fr) * | 2000-04-10 | 2002-05-24 | Oreal | Utilisation de derives d'acide ascorbique pour augmenter la synthese des creramides epidermiques |
FR2808441B1 (fr) * | 2000-05-04 | 2004-06-18 | Oreal | Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau |
FR2808999B1 (fr) * | 2000-05-19 | 2002-11-01 | Oreal | Composition cosmetique sous forme de poudre comprenant un liant particulier |
FR2808998B1 (fr) * | 2000-05-19 | 2002-07-05 | Oreal | Composition cosmetique de maquillage comprenant une phase liante particuliere |
EP1159954A3 (en) * | 2000-05-31 | 2003-01-02 | Shiseido Company, Ltd. | Solid water-in-oil type emulsion cosmetic composition |
US6696049B2 (en) * | 2000-07-10 | 2004-02-24 | The Procter & Gamble Company | Cosmetic compositions |
US6524598B2 (en) * | 2000-07-10 | 2003-02-25 | The Procter & Gamble Company | Cosmetic compositions |
US20020022040A1 (en) * | 2000-07-10 | 2002-02-21 | The Proctor & Gamble Company | Methods of enhancing delivery of oil-soluble skin care actives |
US6409997B1 (en) * | 2000-07-31 | 2002-06-25 | Neutrogena Corporation | Wax cosmetic stick |
FR2813189B1 (fr) * | 2000-08-31 | 2003-02-28 | Oreal | Creme cosmetique moussante pour le traitement des peaux grasses |
FR2820972B1 (fr) * | 2001-02-22 | 2003-05-16 | Oreal | Utilisation comme agent matifiant dans une composition cosmetique d'un polymere ou copolymere alkyle de polylvinylpyrrolidone |
US20020164294A1 (en) * | 2001-02-16 | 2002-11-07 | Kalliope Christophides-Lordi | Methods for producing a matte effect |
FR2820977A1 (fr) * | 2001-02-22 | 2002-08-23 | Oreal | Composition cosmetique matifiante a base de dispersion aqueuse de polytetrafluoroethylene |
US20020192245A1 (en) * | 2001-04-17 | 2002-12-19 | Jensen Claude Jarkae | Morinda Citrifolia (Noni) enhanced protective night cream moisturizer |
US6589514B2 (en) * | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
DE10130963A1 (de) * | 2001-06-27 | 2003-01-16 | Beiersdorf Ag | Verwendung von Bis-Resorcinyltriazinderivaten zur Verbesserung der Wirksamkeit von lipophilen Wirkstoffen in kosmetischen oder dermatologischen Zubereitungen |
US7166292B2 (en) * | 2001-06-29 | 2007-01-23 | The Procter & Gamble Company | Top-biased beneficial components on substrates |
US7005557B2 (en) * | 2001-07-03 | 2006-02-28 | The Procter & Gamble Company | Film-forming compositions for protecting skin from body fluids and articles made therefrom |
US6498197B1 (en) * | 2001-07-25 | 2002-12-24 | Dow Corning Corporation | Temperature insensitive one-phase microemulsions |
FR2829693B1 (fr) * | 2001-09-20 | 2004-02-27 | Oreal | Creme cosmetique moussante |
US20030082219A1 (en) * | 2001-10-01 | 2003-05-01 | The Procter & Gamble Company | Skin care compositions comprising low concentrations of skin treatment agents |
US6776981B2 (en) * | 2002-01-29 | 2004-08-17 | The Gillette Company | Personal care product |
JP3979922B2 (ja) * | 2002-11-08 | 2007-09-19 | 信越化学工業株式会社 | 親水化処理粉体及びこれらを含有する組成物 |
JP3993505B2 (ja) * | 2002-11-14 | 2007-10-17 | 株式会社コーセー | 油中水型乳化化粧料 |
US20040167479A1 (en) * | 2003-02-20 | 2004-08-26 | The Procter & Gamble Company | Hemorrhoid treatment pad |
US20040175347A1 (en) * | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
US7285570B2 (en) * | 2003-04-17 | 2007-10-23 | The Procter & Gamble Company | Compositions and methods for regulating mammalian keratinous tissue |
EP1477155A1 (en) * | 2003-05-16 | 2004-11-17 | The Procter & Gamble Company | Compositions comprising an amidine and an alkane polyol |
BRPI0416052A (pt) * | 2003-10-31 | 2007-01-02 | Procter & Gamble | composição para tratamento de pele contendo ácido deidro acético e ativos para tratamento de pele |
CN1781476B (zh) * | 2004-03-22 | 2013-10-16 | 莱雅公司 | 包含聚甘油化硅氧烷弹性体的化妆品组合物 |
US20060013792A1 (en) * | 2004-07-16 | 2006-01-19 | Jacqueline Fontaine | Solid water-in-oil cosmetic emulsion |
US20070128137A1 (en) * | 2005-12-02 | 2007-06-07 | Naohisa Yoshimi | Water in oil emulsion compositions containing siloxane elastomers |
US20080038360A1 (en) * | 2006-08-11 | 2008-02-14 | Joseph Michael Zukowski | Personal care composition |
US8555207B2 (en) | 2008-02-27 | 2013-10-08 | Qualcomm Incorporated | Enhanced input using recognized gestures |
JP6246650B2 (ja) | 2014-04-11 | 2017-12-13 | タイコエレクトロニクスジャパン合同会社 | 表面実装コネクタ |
-
2003
- 2003-03-04 US US10/379,252 patent/US20040175347A1/en not_active Abandoned
-
2004
- 2004-02-17 US US10/780,267 patent/US20040176273A1/en not_active Abandoned
- 2004-03-04 KR KR1020057016205A patent/KR100825695B1/ko active IP Right Grant
- 2004-03-04 MX MXPA05009392A patent/MXPA05009392A/es active IP Right Grant
- 2004-03-04 CA CA2516501A patent/CA2516501C/en not_active Expired - Lifetime
- 2004-03-04 KR KR1020077011173A patent/KR100786045B1/ko active IP Right Grant
- 2004-03-04 JP JP2005518889A patent/JP4234137B2/ja not_active Expired - Lifetime
- 2004-03-04 WO PCT/US2004/006499 patent/WO2004078158A2/en active Application Filing
- 2004-03-04 EP EP04717359.6A patent/EP1603529B1/en not_active Expired - Lifetime
- 2004-03-04 CN CNB2004800057803A patent/CN100421644C/zh not_active Expired - Lifetime
- 2004-03-04 EP EP15192625.0A patent/EP2997960A1/en not_active Ceased
- 2004-03-04 AU AU2004218346A patent/AU2004218346B2/en not_active Ceased
- 2004-03-04 BR BRPI0408062-9A patent/BRPI0408062A/pt not_active Application Discontinuation
-
2006
- 2006-06-08 HK HK06106585.2A patent/HK1086738A1/zh not_active IP Right Cessation
-
2010
- 2010-07-13 US US12/835,244 patent/US20100278765A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006515329A (ja) | 2006-05-25 |
EP2997960A1 (en) | 2016-03-23 |
US20100278765A1 (en) | 2010-11-04 |
US20040175347A1 (en) | 2004-09-09 |
WO2004078158A3 (en) | 2005-01-13 |
KR20050107479A (ko) | 2005-11-11 |
BRPI0408062A (pt) | 2006-02-14 |
MXPA05009392A (es) | 2005-11-04 |
WO2004078158A2 (en) | 2004-09-16 |
EP1603529B1 (en) | 2016-04-27 |
CN1756528A (zh) | 2006-04-05 |
AU2004218346A1 (en) | 2004-09-16 |
KR100825695B1 (ko) | 2008-04-29 |
KR20070056170A (ko) | 2007-05-31 |
HK1086738A1 (zh) | 2006-09-29 |
CN100421644C (zh) | 2008-10-01 |
CA2516501A1 (en) | 2004-09-16 |
CA2516501C (en) | 2012-07-10 |
US20040176273A1 (en) | 2004-09-09 |
EP1603529A2 (en) | 2005-12-14 |
KR100786045B1 (ko) | 2007-12-17 |
AU2004218346B2 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4234137B2 (ja) | ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整 | |
JP4007480B2 (ja) | スキンケア活性物質の組合せを含有するスキンケア組成物 | |
KR100455470B1 (ko) | 피토스테롤 조성물의 국소 적용을 통한 포유류 케라틴조직 상태의 조절 방법 | |
JP2005521708A (ja) | ビタミンb6組成物の局所適用により哺乳類のケラチン組織の状態を調整するための方法 | |
JP2005503335A (ja) | 糖アミンを含有するスキンケア組成物 | |
KR20020012175A (ko) | 피부 케어 활성제의 배합물을 함유하는 피부 케어 조성물 | |
KR20010109525A (ko) | 포유류의 케라틴 조직 상태의 조절 방법 | |
JP2007515381A (ja) | テトラペプチドとトリペプチドの混合物を含む組成物 | |
JP2002542179A (ja) | スキンケア活性物質の組合せを含有するスキンケア組成物 | |
KR20020011988A (ko) | 포유류의 케라틴 조직 상태의 조절 방법 | |
WO2000069406A1 (en) | Methods of regulating the condition of mammalian keratinous tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080208 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20080509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080609 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080722 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081114 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4234137 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131219 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |